


CURRICULUM VITAE

ALAN SIMON PICKARD

Professor
Department of Pharmacy Systems, Outcomes, and Policy (PSOP)
College of Pharmacy
University of Illinois at Chicago (UIC)
Chicago IL, USA 60612
833 S. Wood St., Rm 164, MC 871
Ph: (312) 413-3357; Fax (312) 996-2954
Email: pickard1@uic.edu



Education

Ph.D. Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada, 2002. (dissertation: responsiveness of generic health status measures in stroke)

B.Sc.Pharm, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada, 1996.

B.Comm Faculty of Business, University of Alberta, Edmonton, Alberta, Canada, 1991.

Licensure

Pharmacist Alberta, Canada, Licensed: 1996-2001.

Positions (Primary Appointment)

2015 - present Professor, Department of Pharmacy Systems, Outcomes and Policy (PSOP), College of Pharmacy, UIC, Chicago, IL, USA

2013 - 2015 Associate professor, Department of Pharmacy Systems, Outcomes and Policy (PSOP), College of Pharmacy, UIC, Chicago, IL, USA

2008 - 2013 Associate professor, Departments of Pharmacy Practice and Pharmacy Administration, College of Pharmacy, UIC, Chicago, IL, USA

2005 – present Assistant director, Center for Pharmacoeconomic Research, College of Pharmacy, UIC, Chicago, IL, USA.

2001 - 2008 Assistant professor, Departments of Pharmacy Practice, UIC, Chicago, IL, USA.

1998 – 2001 Research assistant, Institute of Health Economics, Edmonton, AB, Canada.

1997 – 2001 Staff Pharmacist, Broadmoor Pharmacy, Sherwood Park, AB, Canada.

Other Appointments

2014 – present Chair, Executive Committee, EuroQol Group

2013 – present Director, Graduate Studies, PSOP

2010 – 2014 Deputy chair, Executive Committee, EuroQol Group

2010 – 2013 Co-deputy PI, Chicago-area DEClIDE center

2009 – present Fellow, Institute for Research and Policy, UIC

2006 – present Partner, Second City Outcomes Research LLC

2006 - present Fellow, Honors College, UIC

2005 - 2009 Research associate, Edward Hines Jr. VA Hospital & Center for Management of Complex Chronic Conditions, Chicago, Illinois.

2000 – 2001 Research associate, Health Technology Assessment Unit, Alberta. Heritage Foundation for Medical Research, Edmonton, Alberta.

Memberships and Groups

2009 – present	American Association of Scientists
2004 – present	American College of Clinical Pharmacy (ACCP)
2001 – present	International Society of Quality of Life (ISOQOL)
2001 – present	Institute for Objective Measurement
2000 – present	EuroQol Group
1999 – present	International Society of Pharmacoeconomic & Outcomes Research (ISPOR)
1999 – present	American Association of Colleges of Pharmacy (AAP)
1999 – 2003	Canadian Association of Population Therapeutics (CAPT)
1996 – 2001	Alberta Pharmaceutical Association (APhA)

Awards/Honors

2014	Certificate of excellence in reviewing, Elsevier (J Clin Epid)
2010	Best Poster Health Policy, International Society for Quality of Life Research Annual Conference, London, UK, Oct 27-30 th , 2010 (co-author)
2007	Outstanding reviewer for 2007, Quality of Life Research (Springer media)
2003	New Investigator Award, International Society for Quality of Life Research
2003	Best Overall Oral Presentation, International Society for Quality of Life Research Annual Conference, Czech Republic, Nov 12-14 th , 2003.
2000-01	Alberta Heritage Foundation for Medical Research –Studentship – Incentive Award, Health Research
2000-01	Rx&D – HRF (Health Research Foundation)/CIHR (Canadian Institutes of Health Research) Graduate Research Scholarship in Pharmacy
1999-00	Parke Davis Doctoral Fellowship in Pharmacy Practice Research
1999	J. Gordin Kaplan Travel Award, University of Alberta
1997	Graduate Assistantship Award, Institute of Pharmacoeconomics
1988, 1989	Certificate of Merit Award, University of Alberta

Refereed Publications

1. **Pickard AS**, Johnson JA, Farris KB. The impact of pharmacist interventions on health-related quality of life. *The Annals of Pharmacotherapy* 1999;33:1167-72. PMID: 10573313
2. Johnson JA, Coons SJ, Hays RD, **Pickard AS**. Health status and satisfaction with pharmacy services. *American Journal of Managed of Care* 1999;5(2):163-170. PMID: 10346512
3. **Pickard AS**, Johnson JA, Lau F, Penn A, Noseworthy T. The replicability of the SF-36 by the SF-12 in stroke patients. *Stroke* 1999;30:1213-1217. PMID: 10356102
4. Spooner CH, **Pickard AS**, Menon D. A systematic review of quinolone, cephalosporin and macrolide use in ambulatory care. *Clinical Therapeutics* 1999;21:1951-1972. PMID: 10890266
5. Spooner CH, **Pickard AS**, Menon D. Edmonton Quality Assessment Tool for Drug Utilization Reviews - EQUATDUR-2: The development of a scale to assess the methodological quality of a drug utilization review. *Medical Care* 2000;38(9):948-958. PMID: 10982116
6. Johnson JA, **Pickard AS**. Comparison of the EQ-5D and SF-12 in a general population survey in Alberta, Canada. *Medical Care* 2000;38(1):115-121. PMID: 10630726
7. Johnson JA, **Pickard AS**. Alberta-based SF-12 summary scores. *Archives of Hellenic Medicine* 2001;18(2):136-147.
8. Park HY, Schumock GT, **Pickard AS**, Akhras K. A structured review of the relationship between microalbuminuria and cardiovascular events in patients with diabetes mellitus and hypertension. *Pharmacotherapy* 2003;23(12):1611-1616. PMID: 14695040

9. **Pickard AS**, Johnson JA, Feeny DH, Carriere KC, Shuaib A, Nasser AM. Agreement between self- and proxy assessment in stroke: a comparison of generic HRQL measures. *Stroke*. 2004 Feb;35(2):607-12. PMID: 14726549
10. Nutescu E, **Pickard AS**, Blackburn J, Schumock GT, Ansell J, Wittkowsky A. The implications of direct thrombin inhibitors for anticoagulation clinics. *Pharmacotherapy*. 2004 Sept 24(9):1204-1212. PMID: 15460181
11. **Pickard AS**, Topfer LA, Feeny DF. A structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia. *Journal of the National Cancer Institute Monographs*. 2004 (33): 102-125. PMID: 15504922
12. **Pickard AS**, Nau D, McKercher P, Schumock GT. The importation of prescription medications: the experiences, opinions and intended behaviors of US community pharmacists *Journal of American Pharmacists Association*. 2004;44: 666-672. PMID: 15637849
13. **Pickard AS**, Johnson JA, Feeny DH. Responsiveness of the SF-36, HUI and EQ-5D in Stroke. *Quality of Life Research*. 2005;14:207-219. PMID: 15789955
14. **Pickard AS**, Wang Z, Walton SM, Lee TA. Do different preference-based algorithms for the SF-36 and SF-12 potentially alter decision-making when applied to cost utility analysis? *Health Outcomes and Quality of Life*. 2005 Mar 4;3(1):11. PMID: PMC555748
15. Kramer KM, Bennett CL, **Pickard AS**, Lyons EA, Wolf MS, McKoy JM, Knight SJ. Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. *Clinical Prostate Cancer*. 2005 Jun;4(1):15-23. PMID: 15992457
16. **Pickard AS**, Knight S. A conceptual framework for understanding differences in proxy perspectives. *Medical Care* 2005 May;43(5):493-499. PMID: PMC1188232
17. McCarthy M Jr, Chang CH, **Pickard AS**, Giobbie-Hurder A, Price DD, Jonasson O, Gibbs J, Fitzgibbons R, Neumayer L. Visual analog scales for assessing surgical pain. *Journal of the American College of Surgeons*. 2005 Aug;201(2):245-52. PMID: 16038823
18. McCarthy M Jr, Jonasson O, Chang CH, **Pickard AS**, Giobbie-Hurder A, Gibbs J, Edelman P, Fitzgibbons R, Neumayer L. Assessment of patient functional status after surgery. *Journal of the American College of Surgeons*. 2005 Aug;201(2):171-8. PMID: 16038812
19. **Pickard AS**, Hung SY, McKoy JM, Witt WP, Arseven A, Sharifi R, Wu Z, Knight SJ, McWilliams N, Schumock GT, Bennett CL. Opportunities for disease state management in prostate cancer. *Disease Management*. 2005 Aug;8(4):235-44. PMID: 16117718
20. Calhoun EA, Schumock GT, McKoy JM, **Pickard S**, Fitzner KA, Heckinger EA, Powell EF, McCaffrey KR, Bennett CL. Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer: the 40% rule revisited. *Pharmacoeconomics*. 2005;23(8):767-75. PMID: 16097839
21. McKoy JM, Lyons EA, Obadina E, Carson K, **Pickard AS**, Schellhammer P, McLeod D, Boyd CE, McWilliams N, Sartor O, Schumock GT, McCaffery K, Bennett CL. Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. *Journal of Clinical Oncology*. 2005 Dec 1;23(34):8894-905. PMID: 16314650
22. Wolf MS, Fitzner KA, Powell EF, McCaffrey KR, **Pickard AS**, McKoy JM, Lindenberg J, Schumock GT, Carson KR, Ferreira MR, Dolan NC, Bennett CL. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans. *Journal of Clinical Oncology*. 2005 Dec 1;23(34):8877-83. PMID: 16314648

23. **Pickard AS**, Dalal MR, Bushnell D. A comparison of depressive symptoms in stroke and primary care: applying Rasch models to evaluate the CES-D scale. *Value in Health* 2006;9(1):59-64. PMID: 16441526
24. **Pickard AS**, Dobrez D, Cella D. Empirically testing assumptions underlying the development of a set of societal weights for the FACT-L. *Pharmacoeconomics* 2006;24(3):293-4. PMID: 16519550
25. Wolf MS, Knight SJ, Lyons EA, Durazo-Arvizu R, **Pickard AS**, Arseven A, Arozullah A, Colella K, Ray P, Bennett CL. Relation between literacy, race, and PSA level among men with newly diagnosed prostate cancer. *Urology* 2006; 68:89-93. PMID: 16844451
26. **Pickard AS**, Hung S-Y. An update on evidence of clinical pharmacy services' impact on health-related quality of life. *Annals of Pharmacotherapy* 2006;40(9):1623-34. Epub 2006 Aug 15. PMID: 16912249
27. **Pickard AS**. Towards supporting scholarship in research by clinical pharmacy faculty. *Pharmacy Practice*. Vol 4(4), 2006. <http://www.pharmacypractice.org/vol04/04/toc.htm>
28. Krueger CD, West PM, Sargent MR, Lodolce AE, **Pickard AS**. Biphosphonate-induced osteonecrosis. *Annals of Pharmacotherapy* 2007;41(2):276-84. PMID: 17299010
29. **Pickard AS**, De Leon MC, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer. *Medical Care* 2007;45(3): 259-263. PMID: 17304084
30. **Pickard AS**, Wilke C, Lin HW, Lloyd A. EQ-5D health utilities in studies of cancer: *PharmacoEconomics*. *Pharmacoeconomics*. 2007;25(5):365-384. PMID: 17488136
31. Lee TA, **Pickard AS**, Bartle B, Weiss K. Osteoarthritis: a comorbid marker for longer life? *Annals of Epidemiology*. 2007;17(5):380-384. PMID: 17462546
32. Dobrez D, Cella D, **Pickard AS**, Lai JS, Nickolov A. Estimation of patient preference-based utility weights from the functional assessment of cancer therapy - general. *Value in Health*. 2007;10(4):266-72. PMID: 17645681
33. Lee TA, **Pickard AS**. Azelastine for allergic rhinitis: a meta-analysis. *Pharmacotherapy*. 2007;27(6):852-9. PMID: 17542768
34. **Pickard AS**, Kohlmann T, Janssen MF, Bonsel G, Rosenbloom S, Cella D. Evaluating Equivalency Between Response Systems: Application of the Rasch Model to a 3-Level and 5-Level EQ-5D. *Medical Care*. 2007 Sept;45(9):812-819. PMID: 17712251
35. Hung SY, **Pickard AS**, Witt WP, Lambert BL. Pain and depression in caregivers affected their perception of pain in stroke patients. *Journal of Clinical Epidemiology*. 2007 Sep;60(9):963-70. PMID: 17689813
36. **Pickard AS**, Neary M, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. *Health and Quality of Life Outcomes*. 2007 Dec 21;5(1):70. PMID: PMC2248572. [erratum: *Health Qual Life Outcomes* 2010 Jan 13;8(1)].
37. **Pickard AS**, Schumock GT, Frye C, Becker R. Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting. *Pharmacotherapy*. 2008;28(3):376-92. PMID: 18294117
38. **Pickard AS**, Wilke CT, Jung E, Lee TA. Use of a preference-based measure of health (EQ-5D) in asthma and COPD. *Respiratory Medicine*. 2008;102(4):519-36. PMID: 18180151

39. Lin HW, **Pickard AS**, Mahady GB, Popovich, NG. Conceptual development of a measure to assess pharmacists' knowledge of herbal and dietary supplements. *American Journal of Pharmaceutical Education*. 2008 Jun 15;72(3):59. PMID: PMC2508720
40. Lee TA, **Pickard AS**, Au DH, Bartle B, Weiss KB. Risk of death associated with respiratory medications for recently diagnosed chronic obstructive pulmonary disease. *Annals of Internal Medicine*. 2008;149(6):380-390. PMID: 18794557
41. Jung E, **Pickard AS**, Salmon JW, Bartle B, Lee TA. Medication adherence and persistence in the last year of life in COPD patients. *Respiratory Medicine*. 2009 Apr;103(4):525-34. Epub 2009 Jan 12. PMID: 19136240
42. **Pickard AS**, Lin HW, Knight SJ, Hung S-Y, Chang C-H, Sharifi R, Bennett CL. Proxy assessment of HRQL in African American and white respondents with prostate cancer: the importance of perspective. *Medical Care*. 2009 Feb;47(2):176-83. PMID: 19169118
43. Jolly M, **Pickard AS**, Wilke C, Mikolaitis RA, Teh LS, McElhone K, Fogg L, Block JA. Lupus specific health outcome measure for US patients: The LupusQoL- US Version(C). *Annals of Rheumatic Diseases*. 2009 Jan 6. [Epub ahead of print] PMID: 19126561
44. **Pickard AS**, Jung E, Bartle B, Weiss KB, Lee TA. Coded causes of death and timing of COPD diagnosis. *COPD: Journal of Chronic Obstructive Pulmonary Disease* 2009 Feb;6(1):41-7. PMID: 19229707
45. Wilke CT, **Pickard AS**, Walton SM, Mook J, Kohlmann T, Lee TA. Statistical implications of utility weighted and equally weighted HRQL measures: an empirical study. *Health Economics*. 2009 Feb 26. [Epub ahead of print] PMID: 19248149
46. Aggarwal R, Wilke CT, **Pickard AS**, Vats V, Mikolaitis R, Fogg L, Block JA, Jolly M. Psychometric Properties of the EuroQol-5D and Short Form-6D in Patients with Systemic Lupus Erythematosus. *Journal of Rheumatology*. 2009 Apr 15. [Epub ahead of print] PMID: 19369452
47. **Pickard AS**, Shaw JW, Lin HW, Trask PC, Aaronson N, Lee TA, Cella D. A Patient-Based Utility Measure of Health for Clinical Trials of Cancer Therapy Based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. *Value in Health*. 2009 Apr 23. [Epub ahead of print] PMID: 19402850
48. Snedecor SJ, Botteman MF, Bojke C, Schaefer K, Barry N, **Pickard AS**. Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. *Sleep*. 2009 Jun 1;32(6):817-24. PMID: PMC2690570
49. Schumock GT, **Pickard AS**. Comparative effectiveness research: relevance and applications to pharmacy. *American Journal of Health Systems Pharmacy*. 2009 Jul 16;66(14):1278-86. PMID: 19574602
50. Lee TA, Wilke CT, Joo M, Krishnan J, Schumock GT, **Pickard AS**. Outcomes associated with use of tiotropium in COPD patients. *Archives of Internal Medicine*. 2009 Aug 10;169(15):1403-10.
51. Lee TA, **Pickard AS**, Bartle B, Schumock GT, Weiss KB. Outcomes associated with theophylline use in COPD patients. *Pharmacotherapy*. 2009 Sept;29(9):1039-53. PMID: 19698009
52. Shaw JW, **Pickard AS**, Yu S, Chen S, Iannacchione VG, Johnson JA, Coons SJ. A median model for predicting united states population-based EQ-5D health state preferences. *Value in Health*. 2010 Mar;13(2):278-88. Epub 2009 Dec 4. PubMed PMID: 19961566.
53. Shaw JW, **Pickard AS**, Yager RR. Application of directional statistics to health state valuation: a commentary on Craig and Oppe. *Social Science in Medicine*. 2010 Aug;71(3):429-30. Epub 2010 May 12. PubMed PMID: 20553854.

54. **Pickard AS**, Neary M, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer: erratum. *Health Qual Life Outcomes* 2010 Jan 13;8(1).
55. Snedecor SJ, Botteman MF, Schaefer K, Sarocco P, Barry N, **Pickard AS**. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. *Journal of Mental Health Policy and Economics*. 2010 Mar;13(1):27-35. PubMed PMID: 20571180.
56. Lau DT, Berman R, Halpern L, **Pickard AS**, Schrauf R, Witt W. Exploring factors that influence informal caregiving in medication management for home hospice patients. *Journal of Palliative Medicine*. 2010 Sep;13(9):1085-90. PubMed PMID: 20836633.
57. Jagasia MH, Savani BN, Neff A, Dixon S, Chen H, **Pickard AS**. Outcome, toxicity profile and cost analysis of autologous stem cell mobilization. *Bone Marrow Transplantation*. 2010 Nov 1. [Epub ahead of print] PubMed PMID: 21042307.
58. Janssen MF, Lubetkin E, Sekhobo J, **Pickard AS**. The use of the EQ-5D preference-based health status measure in adults with type 2 diabetes. *Diabetic Medicine* 2011;28: 395-411.
59. Lin HW, **Pickard AS**, Mahady GB, Karabatsos G, Crawford SY, Popovich NG. An instrument to evaluate pharmacists' patient counseling on herbal and dietary supplements. *American Journal of Pharmaceutical Education*. 2010 Dec 15;74(10):192. PubMed PMID: 21436933.
60. Jolly M, **Pickard AS**, Mikolaitis RA, Cornejo J, Sequeira W, Cash TF, Block JA. Body Image in Patients with Systemic Lupus Erythematosus. *International Journal of Behavioral Medicine*. 2011 Mar 6. [Epub ahead of print] PubMed PMID: 21380770.
61. **Pickard AS**, Yang Y, Lee TA. Comparison of health-related quality of life measures in chronic obstructive pulmonary disease. *Health and Quality of Life Outcomes*. 2011 Apr 18;9(1):26. [Epub ahead of print] PubMed PMID: 21501522.
62. Liu FX, Alexander GC, Crawford SY, **Pickard AS**, Hedeker D, Walton SM. The Impact of Medicare Part D on Out-of-Pocket Costs for Prescription Drugs, Medication Utilization, Health Resource Utilization, and Preference-Based Health Utility. *Health Services Research*. 2011 Aug;46(4):1104-1123.
63. Cella D, **Pickard AS**, Duh MS, Guerin A, Mishagina N, Anràs L, Neary MP, McCann L, Hodge R, Sternberg CN. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomized phase III trial. *European Journal of Cancer*. 2011 Jun 18. [Epub ahead of print]
64. **Pickard AS**, Lee TA, Solem CT, Joo MJ, Schumock GT, Krishnan JA. Prioritizing comparative-effectiveness research topics via stakeholder involvement: an application in COPD. *Clinical and Pharmacological Therapeutics*. 2011 Dec;90(6):888-92.
65. Jolly M, **Pickard AS**, Sequeira W, Wallace DJ, Solem CT, Mikolaitis RA, Fogg L, Weisman MH, Block JA, Cash TF. A brief assessment tool for body image in systemic lupus erythematosus. *Body Image*. 2012 Mar;9(2):279-84. Epub 2011 Dec 8. PubMed PMID: 22154813.
66. Solem CT, Lee TA, Joo MJ, Lambert BL, Walton SM, **Pickard AS**. Complexity of medication use in newly diagnosed chronic obstructive pulmonary disease patients. *American Journal of Geriatric Pharmacotherapy*. 2012 Apr;10(2):110-122.e1. Epub 2012 Jan 26. PubMed PMID: 22280978.
67. **Pickard AS**, Ray S, Ganguli A, Cella D. Comparison of FACT- and EQ-5D-based utility scores in cancer. *Value in Health*. 2012 Mar-Apr;15(2):305-11. Epub 2012 Feb 2. PubMed PMID: 22433762.
68. Jolly M, **Pickard AS**, Block JA, Kumar RB, Mikolaitis RA, Wilke CT, Rodby RA, Fogg L, Sequeira W, Utset TO, Cash TF, Moldovan I, Katsaros E, Nicassio P, Ishimori ML, Kosinsky M, Merrill JT,

- Weisman MH, Wallace DJ. Disease-specific patient reported outcome tools for systemic lupus erythematosus. *Seminars in Arthritis and Rheumatism*. 2012 Aug;42(1):56-65. Epub 2012 Apr 4. PubMed PMID: 22480408.
69. Samp JC, Schumock GT, **Pickard AS**. Retracted publications in the drug literature. *Pharmacotherapy*. 2012 Jul;32(7):586-95.
 70. Lin FJ, Longworth L, **Pickard AS**. Evaluation of content on EQ-5D as compared to disease-specific utility measures. *Quality of Life Research*. 2012 Jun 23. [Epub ahead of print] PubMed PMID: 22729670.
 71. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, **Pickard AS**. Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets. *Value in Health*. 2012 Jul;15(5):708-15. Epub 2012 May 24. PubMed PMID: 22867780.
 72. Lin FJ, Lee TA, Wong PS, **Pickard AS**. Evaluation of changes in guidelines for medication management of stable chronic obstructive pulmonary disease. *Journal of Evaluation in Clinical Practice*. 2013 Oct; 19(5):953-60. PubMed PMID: 22892033.
 73. **Pickard AS**, Tawk R, Shaw JW. The effect of chronic conditions on stated preferences for health. *European Journal of Health Economics*. 2013 Aug;14(4):697-702. Epub 2012 Sep 1. PubMed PMID: 22941035.
 74. Neufeld EJ, Recht M, Sabio H, Saxena K, Solem CT, **Pickard AS**, Gut RZ, Cooper DL. Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia. *Value in Health*. 2012 Sep;15(6):916-25.
 75. Tsai HH, Lin HW, **Pickard AS**, Tsai HY, Mahady GB. Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. *International Journal of Clinical Practice*. 2012 Nov;66(11):1056-1078.
 76. Young G, Solem CT, Hoffman K, Kabawat J, **Pickard AS**, Gut RZ, Cooper DL. Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE). *Journal of Blood Medicine*. 2012;3:131-8. Epub 2012 Nov 7. PubMed Central PMCID: PMC3496408.
 77. Janssen MF, **Pickard AS**, Golicki D, Gudex C, Niewada M, Scalone L, Swinburn P, Busschbach J. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Quality of Life Research*. 2013 Sep;22(7):1717-27. Epub 2012 Nov 25. PubMed PMID:23184421; PubMed Central PMCID: PMC3764313.
 78. Shaughnessy P, Chao N, Shapiro J, Walters K, McCarty J, Abhyankar S, ShayaniS, Helmons P, Leather H, Pazzalia A, **Pickard S**. Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature. *Biology of Blood Marrow Transplantation*. 2013 Sep;19(9):1301-9. doi:10.1016/j.bbmt.2013.05.008. Epub 2013 May 14. PubMed PMID: 23685251.
 79. Craig BM, **Pickard AS**, Stolk E, Brazier JE. US valuation of the SF-6D. *Medical Decision Making*. 2013 Aug;33(6):793-803. doi: 10.1177/0272989X13482524. Epub 2013 Apr 29. PubMed Central PMCID: PMC3740344.
 80. Lin FJ, Samp J, Munoz A, Wong PS, **Pickard AS**. Evaluating change using patient-reported outcome measures in knee replacement: the complementary nature of the EQ-5D index and VAS scores. *European Journal of Health Economics*. 2013 Jun 14. [Epub ahead of print] PubMed PMID: 23765331.

81. Craig BM, **Pickard AS**, Lubetkin EI. Health problems are more common, but less severe when measured using newer EQ-5D versions. *Journal of Clinical Epidemiology*. 2014 Jan;67(1):93-9. doi: 10.1016/j.jclinepi.2013.07.011. Epub 2013 Sep 24. PubMed PMID: 24075597.
82. Patel HN, Ursan ID, Zueger PM, Cavallari LH, **Pickard AS**. Stakeholder Views on Pharmacogenomic Testing. *Pharmacotherapy*. 2014 Feb;34(2):151-65. Epub 2013 Oct 24. doi: 10.1002/phar.1364. [Epub ahead of print] PubMed PMID: 24167008.
83. Craig BM, Hays RD, **Pickard AS**, Cella D, Revicki DA, Reeve BB. Comparison of US panel vendors for online surveys. *Journal of Medical Internet Research*. 2013 Nov 29;15(11):e260. doi: 10.2196/jmir.2903. PubMed PMID: 24292159; PubMed Central PMCID: PMC3869084.
84. Craig BM, Reeve BB, Cella D, Hays RD, **Pickard AS**, Revicki DA. Demographic Differences in Health Preferences in the United States. *Medical Care*. 2013 Dec 26. [Epub ahead of print] PubMed PMID: 24374420.
85. Prieto-Centurion V, Markos MA, Ramey NI, Gussin HA, Nyenhuis SM, Joo MJ, Prasad B, Bracken N, Didomenico R, Godwin PO, Jaffe HA, Kalhan R, **Pickard AS**, Pittendrigh BR, Schatz B, Sullivan JL, Thomashow BM, Williams MV, Krishnan JA. Interventions to Reduce Rehospitalizations Following Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review. *Annals of American Thoracic Society*. 2014 Mar;11(3):417-24.
86. Kuspinar A, Linch L, **Pickard S**, Mayo NE. Using existing data to identify candidate items for a prototype preference-based measure for multiple sclerosis. *Quality of Life Research*. 2014 Jun;23(5):1445-57. doi: 10.1007/s11136-013-0604-5. Epub 2013 Dec 15.
87. Lee WJ, Lee TA, **Pickard AS**, Caskey RN, Schumock GT. Drugs Associated with Adverse Events in Children and Adolescents. *Pharmacotherapy*. 2014 Sep;34(9):918-26. doi: 10.1002/phar.1455. Epub 2014 Jul 3. PubMed PMID: 24990656.
88. Krabbe PF, Devlin NJ, Stolk EA, Shah KK, Oppe M, van Hout B, Quik EH, **Pickard AS**, Xie F. Multinational evidence of the applicability and robustness of discretechoice modeling for deriving EQ-5D-5L health-state values. *Med Care*. 2014 Nov;52(11):935-43. PubMed PMID: 25100229; PubMed Central PMCID: PMC4196797.
89. Lin FJ, **Pickard AS**, Krishnan JA, Joo MJ, Au DH, Carson SS, Gillespie S, Henderson AG, Lindenauer PK, McBurnie MA, Mularski RA, Naureckas ET, Vollmer WM, Lee TA; CONCERT Consortium. Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form. *BMC Medical Research Methodology*. 2014 Jun 16;14:78. PubMed PMID: 24934150; PubMed Central PMCID: PMC4072614.
90. Recht M, Neufeld EJ, Sharma VR, Solem CT, **Pickard AS**, Gut RZ, Cooper DL. Impact of Acute Bleeding on Daily Activities of Patients with Congenital Hemophilia with Inhibitors and Their Caregivers and Families: Observations from the Dosing Observational Study in Hemophilia (DOSE). Epub 2014 Aug 14. PubMed PMID: 25236999.
91. Cheng WH, Patel H, Lee WJ, Lin FJ, **Pickard AS**. Positive Outcomes of Varicose Vein Surgery: The Patient Perspective. *Patient*. 2014 Oct 25. [Epub ahead of print] PubMed PMID: 25344103.
92. Golicki D, Niewada M, Buczek J, Karlińska A, Kobayashi A, Janssen MF, **Pickard AS**. Validity of EQ-5D-5L in stroke. *Qual Life Res*. 2015 Apr;24(4):845-50 Epub 2014 Oct 28. PubMed PMID: 25347978.
93. Craig BM, Reeve BB, Brown PM, Cella D, Hays RD, Lipscomb J, **Pickard AS**, Revicki DA. Valuation of Health Outcomes Measured Using the PROMIS-29. *Value in Health* 2014 Dec;17(8):846-53.

94. Golicki D, Niewada M, Karlińska A, Buczek J, Kobayashi A, Janssen MF, **Pickard AS**. Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. *Qual Life Res.* 2014 Nov 26. [Epub ahead of print] PubMed PMID: 25425288.
95. Craig BM, **Pickard AS**, Rand-Hendriksen K. Do health preferences contradict ordering of EQ-5D labels? *Qual Life Res.* 2015 Jul;24(7):1759-65. PubMed PMID: 25519940.
96. **Pickard AS**. Is it Time to Update Societal Value Sets for Preference-Based Measures of Health? *Pharmacoeconomics.* 2015 Mar;33(3):191-2 PubMed PMID: 25586758.
97. Ursa ID, Jiang R, Pickard EM, Lee TA, Ng D, **Pickard AS**. Emergence of BCR-ABL Kinase Domain Mutations Associated with Newly Diagnosed Chronic Myeloid Leukemia: A Meta-Analysis of Clinical Trials of Tyrosine Kinase Inhibitors. *J Manag Care Spec Pharm.* 2015 Feb;21(2):114-22. PubMed PMID: 25615000.
98. Xie F, **Pickard AS**, Krabbe PF, Revicki D, Viney R, Devlin N, Feeny D. A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). *Pharmacoeconomics.* 2015 Aug;33(8):867-77. PubMed PMID: 26026667.
99. Lee W-J, Lee TA, **Pickard AS**, Shoaibi A, Schumock GT. Using linked electronic data to validate algorithms for health outcomes in administrative databases. *J. Comp. Eff. Res.* 4(4), 359–366 (2015).
100. Norman R, Viney R, Aaronson NK, Brazier JE, Cella D, Costa DS, Fayers PM, Kemmler G, Peacock S, **Pickard AS**, Rowen D, Street DJ, Velikova G, Young TA, King MT. Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format. *Qual Life Res.* 2016 Mar;25(3):637-49. doi: 10.1007/s11136-015-1115-3. Epub 2015 Sep 5. PubMed PMID: 26342928.
101. Saraf SL, Oh AL, Patel PR, Jalundhwala Y, Sweiss K, Koshy M, Campbell-Lee S, Gowhari M, Hassan J, Peace D, Quigley JG, Khan I, Molokie RE, Hsu LL, Mahmud N, Levinson DJ, **Pickard AS**, Garcia JG, Gordeuk VR, Rondelli D. Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. *Biol Blood Marrow Transplant.* Biol Blood Marrow Transplant. 2016 Mar;22(3):441-8. doi: 10.1016/j.bbmt.2015.08.036. Epub 2015 Sep 5. PubMed PMID: 26348889
102. King MT, Costa DS, Aaronson NK, Brazier JE, Cella DF, Fayers PM, Grimison P, Janda M, Kemmler G, Norman R, **Pickard AS**, Rowen D, Velikova G, Young TA, Viney R. QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30. *Qual Life Res.* Qual Life Res. 2016 Mar;25(3):625-36.
103. **Pickard AS**, Jiang R, Lin HW, Rosenbloom S, Cella D. Using Patient-Reported Outcomes to Compare Relative Burden of Cancer: EQ-5D and Functional Assessment of Cancer Therapy-General in Eleven Types of Cancer. *Clin Ther.* 2016 Mar 31. pii:S0149-2918(16)30146-1. doi: 10.1016/j.clinthera.2016.03.009. [Epub ahead of print] PubMed PMID: 27041407.

Manuscripts in Progress/ Under Review

1. Jalundhwala Y, Pickard AS. Performance of the EQ-5D-5L in a large community survey. (in progress).
2. Jalundhwala Y, Pickard AS. Relationship between psychological dispositions, health behaviors and health-related quality of life. (in progress).
3. Pickard AS, Popovich N, Smith E, Fong K, Jalundhwala Y. Development of a measure of satisfaction with mentoring relationships. In development.

4. Norman R, King MT, Costa D, Aaronson N, Cella D, Fayers P, Kemmler G, **Pickard AS**, Street D, Velikova G, Young T, Viney R on behalf of the MAUCa Consortium. Importance vs severity in the development of utility-based measures of health. In prep.
5. Jalundhwala Y, Shaw JW, **Pickard AS**. Logical inconsistencies as a criterion for selecting health states in EQ-5D valuation studies. *Eur J Health Econ.*(submitted Oct 2014)
6. Jalundhwala Y, Dang J, Gor D, Lin FJ, **Pickard AS**. Using Baseline Patient Self-Rating of Health to Predict the Outcomes of Hip Replacement Surgery. In prep.
7. Crawford SY, Tawk R, Awe C, **Pickard AS**. Pharmacy Student Perceptions of Cultural Competence and Diversity: Assessing Knowledge, Attitudes, Skills, and Encounters. Submitted April 2015.
8. Shaw J, Luo X, **Pickard AS**, Walton S. Efficiency of estimation with the US population median-based EQ-5D index: findings from the Medical Expenditure Panel Survey. *Health Economics* (under review)
9. **Pickard AS**, Hung, YT, Lin FJ, Lee TA. Preferences for EQ-5D health states among patients undergoing knee replacement surgery: are they stable? Submitted to *Med Care* Jan 24, 2016.
10. Lambert BL, **Pickard AS**, Duhig J, Galanter W, Solem CT, Lodolce AE, Koronkowski M, Schiff GD. Conceptualizing and developing a measure of formulary culture. *JASP* (revise and resubmit)

Letters

Pickard S. Canadian, not American (islet cell transplantation researchers). *The Pharmaceutical Journal* 2000;265(7120):652.

Pickard AS, Schumock GT. Aspirin Use May Change Cost-effectiveness of COX-2 Inhibitors. *Arch Intern Med.* 2002;162(22):2637-9.

Pickard AS, Topfer LA, Feeny DH. Response to Davis. Re: A structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia. *Journal of the National Cancer Institute Monographs.* Dec 2005.

Books

Pickard, AS (Editor). 21st scientific plenary meeting of the euroqol group. Chicago: UIC office of publication services. 2005. ISBN: 0-9770118-0-1.

Book Chapters/Monographs/Reports

Monograph contributor. *Health Care Cost, Quality, and Outcomes. ISPOR Book of Terms.* Editors: Berger ML, Bingefors K, Hedblom EC, Pashos CL, Torrance GW. 2003.

Lee TA, **Pickard AS**. Chapter 4: Exposure definition and measurement. In: *Developing a protocol for observational comparative effectiveness research: a user's guide.* Edited by: Priscilla Velentgas, Nancy A Dreyer, Parivash Nourjah, Scott R Smith, Marion M Torchia. AHRQ Publication No. 12(13)-EHC099. Rockville, MD: Agency for Healthcare Research and Quality; January 2013.
www.effectivehealthcare.ahrq.gov/Methods-OCER.cfm.

ISOQOL Dictionary of Quality of Life and Health Outcomes Measurement (Editor: Nancy E. Mayo, PhD) <http://www.isoqol.org/>. 2015. <http://www.amazon.com/ISOQOL-Dictionary-Quality-Outcomes-Measurement/dp/0996423109>.

Samp JC, Jalundhwala Y, Perez A, **Pickard AS**. Basic principles of pharmacoeconomics. Chapter 22, pages 455-483. In: The Clinical Practice of Drug Information. Ed: Michael Gabay. Jones and Barlett Learning: Burlington MA. 2015. <http://www.amazon.com/The-Clinical-Practice-Drug-Information/dp/128402623X>

Pickard AS, Law E, Crawford SY, Manasse HR, Hopkins T, Lee TA, Sharp LK, Suda K, Cosel G. National assessment of state oversight of sterile drug compounding. February 2016. Available at: http://www.pewtrusts.org/~media/assets/2016/02/national_assessment_of_state_oversight_of_sterile_drug_compounding.pdf

Technology Disclosures

LupusPRO©. A patient report outcome measure of quality of life and quality of medical care in Lupus. Developers: Meenakshi Jolly, MD, MS, **A. Simon Pickard**, PhD, Joel A. Block, MD. Disclosed to RUSH University and UIC Office of Technology Management, April 17th, 2007. Licensed to Multinational Pharma Companies, Foundations.

Non-Refereed Reports and Working Papers

1. Johnson JA, **Pickard AS**. Alberta-based SF-12 summary scores. Edmonton, AB: Institute of Pharmaco-Economics; 1998. Working Paper 98-2.
2. Johnson JA, **Pickard AS**. Comparison of the EQ-5D and SF-12 in a general population survey in Alberta, Canada. Edmonton, AB: Institute of Pharmaco-Economics; 1998. Working Paper 98-6.
3. Spooner CH, **Pickard AS**, Menon D. A systematic review of quinolone, cephalosporin and macrolide use in ambulatory care. Edmonton, AB: Institute of Health Economics; 1999. Working Paper 99-3.
4. ***Pickard AS**, Topfer LA. A rapid structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia. Bethesda, MD Commissioned Report for the Outcomes Research Branch, National Cancer Institute USA: 1999.
5. *Johnson JA, **Pickard AS**, Conner-Spady B. Health-related quality of life as a predictor of future physician visits and hospitalization. Proceedings of the 17th Plenary meeting of the Euroqol group. Sept 28-29, 2000, Pamplona, Spain.
6. *Johnson JA, Conner-Spady B, **Pickard AS**. HRQL in diabetics compared to those without chronic conditions (discussion paper). Proceedings of the 17th Plenary meeting of the Euroqol group. Sept 28-29, 2000, Pamplona, Spain.
7. Fassbender K, **Pickard AS**. A policy impact analysis of pharmaceutical cost containment policies in Alberta. Edmonton, AB: Institute of Health Economics; 2000. Working Paper 00-12.
8. **Pickard AS**, Topfer LA, Feeny DF. A rapid structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia. Edmonton, AB: Institute of Health Economics; 2000. Working Paper 00-01.
9. **Pickard AS**, Dalal M, Johnson JA. The influence of depression on agreement between proxy assessment and patient self-assessment in stroke using the EQ-5D and SF-36. Proceedings of the 19th scientific plenary meeting of the Euroqol group. Sept 12-14, 2002, York, England.
10. Selai C, Johnson JA, **Pickard AS**. The collection of EuroQol EQ-5D data via proxies. Reference document for EQ-5D users. Tabled at the 19th Plenary meeting of the Euroqol group. Sept 12-14, 2002, York, England. Available through <http://www.euroqol.org/web/users/alternative.php>
11. **Pickard AS**, Johnson JA, Feeny DH. Responsiveness of Generic Health-Related Quality of Life measures in Stroke. Proceedings of the 19th Plenary meeting of the Euroqol group. Sept 12-14, 2002, York, England.

12. **Pickard AS**, Lee T. Refinement of proxy versions of EQ-5D: a US-based pilot study. Proceedings of the 21st scientific plenary meeting of the Euroqol group. Sept 16-18th, 2004, Chicago, IL, USA.
13. **Pickard AS**, Lin M, de Leon C. Proxy rating of HRQL using EQ-5D and EORTC QLQ: Does proxy viewpoint affect assessment? Proceedings of the 22nd scientific plenary meeting of the EuroQol group. Sept 15-18th, 2005, Oslo, Norway.
14. Lee T, **Pickard AS**, Weiss K. Outcomes of COPD Management. Draft report for the Agency for Healthcare Research and Quality by the Chicago area DEClDE Center (PI: Schumock GT). Contract no. HHS290200500381, Task Order No. 1. Submitted March 31, 2006.
15. **Pickard AS**, Kohlmann T, Janssen MF, Bonsel G, Cella D, Rosenbloom S. Come together: development of a valuation crosswalk between the 3 level and 5 level EQ-5D using item response theory. Proceedings of the 23st scientific plenary meeting of the Euroqol group. Sept 14-16th, 2006, Barcelona, Spain.
16. **Pickard AS**, Wilke C, Lin HW, Lloyd A. Use of the EQ-5D in studies of cancer: estimates of HRQL in subtypes of cancer and psychometric properties. Proceedings of the 23st scientific plenary meeting of the Euroqol group. Sept 14-16th, 2006, Barcelona, Spain.
17. **Pickard AS**, De Leon MC, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5 level version: evidence from a US-based multicenter study of cancer patients. Proceedings of the 23st scientific plenary meeting of the Euroqol group. Sept 14-16th, 2006, Barcelona, Spain.
18. **Pickard AS**, Wilke CS, Jung E, Patel S, Stavem K, Lee TA. Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Proceedings of the 24st scientific plenary meeting of the Euroqol group. Sept 14-16th, 2007, The Hague, Netherlands.
19. **Pickard AS**. Career pathways in pharmacoeconomics and outcomes research. ISPOR Connections Vol 13(5): Oct 15, 2007.
20. Craig B, **Pickard A**. Variability in QALY Values for Chronic Conditions. Proceedings of the 26th scientific plenary meeting of the EuroQol Group (ed: dePouvreville G). Sept 15-18th, 2009, Paris, France. pgs:155-164.
21. Wilke CS, Karabatsos G, **Pickard AS**. Application of Kernel Regression IRT for Evaluation of EQ-5D 3L and 5L Systems. Proceedings of the 25st scientific plenary meeting of the Euroqol group (eds: Scalone L and Mantovani L). Sept 11-12th, 2008, Baveno, Italy.
22. Wilke CS, **Pickard AS**, Walton SM, Mook J, Kohlmann T, Lee TA. Statistical Implications of Utility Weighted and Equally Weighted HRQL Measures: An Empirical Study. Proceedings of the 25st scientific plenary meeting of the Euroqol group. Sept 11-12th, 2008, Baveno, Italy.
23. **Pickard AS**, Lin FJ. Is EQ-5D inferior in content to disease-specific utility measures? Proceedings of the 25st scientific plenary meeting of the Euroqol group Athens, Greece. (ed: Yfantopoulos J). Sept 11-12th, 2010, Proceedings:243-271.
24. Shaw J, Luo X, **Pickard AS**, Walton S. Efficiency of estimation with the US population median-based EQ-5D index: findings from the Medical Expenditure Panel Survey. Proceedings of the 25st scientific plenary meeting of the Euroqol group (ed: Yfantopoulos J). Sept 11-12th, 2010, Athens, Greece.
25. Janssen M, Lubetkin E, **Pickard A**. The Use of the EQ-5D Preference-Based Health Status Measure in Adults with Type 2 Diabetes Mellitus. . Proceedings of the 27st scientific plenary meeting of the Euroqol group (ed: Yfantopoulos J). Sept 11-12th, 2010, Athens, Greece.
26. **Pickard AS**, Tawk R, Shaw J. The effect of chronic conditions on stated preferences for health. 28th Scientific Plenary Meeting of the EuroQol Group, Oxford, United Kingdom, September 15-17 2011, Lloyd A, host. Proceedings:135-144.
27. Lamers L, Gudex C, **Pickard AS**, Rabin R, on behalf of the EuroQol Group. Improving EQ-5D instruments and exploring new valuation techniques. ISPOR connections January/February 2012, Vol 18, No. 1: 10-11.
28. Janssen M, Busschbach J, Golicki D, Niewada M, Scalone L, Swinburn P, **Pickard A**. Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in 8 patient groups. 28th Scientific Plenary Meeting of the EuroQol Group, Oxford, United Kingdom, September 15-17 2011, Lloyd A, host. Proceedings: 145-160.
29. Dabbous F, Kothari S, **Pickard AS**. Survey of the use of ISPOR resources by Chicago Regional Chapter members. ISPOR connections May/June 2012, Vol 18, No. 3.
30. Lin FJ, Samp J, Munoz A, Wong PS, **Pickard AS**. Evaluating change using patient-reported outcome measures in knee replacement: the complementary nature of the EQ-5D index and VAS

- scores. 29th Scientific Plenary Meeting of the EuroQol Group, Rotterdam, the Netherlands, September 13-15 2012, Busschbach J, host. Proceedings: 27-39.
31. Schumock GT, Lee TA, **Pickard AS**, Lee WJ, Patel H, Dilokthornsakul P, Shoaibi A, Archdeacon P. Mini-Sentinel Methods: Alternative Methods for Health Outcomes of Interest Validation. Silver Spring, MD: Food and Drug Administration, Sentinel Initiative, Mini-Sentinel Program. Available at http://www.minisentinel.org/methods/outcome_validation/details.aspx?ID=105. Accessed September 25, 2013.

Abstracts/Symposia/Workshops (contributed to meetings of academic societies: [published abstracts])

1. (symposium) **Pickard AS**, Xie F, Pullenayegum E, Johnson J. Variation in health state preferences across location and international populations: East doesn't meet West. Canadian Agency for Drugs and Technologies in Health. Annual Meeting, Ottawa, Canada. April 11-12, 2016.
2. (workshop) **Pickard AS**, Xie F, Pullenayegum E, Johnson J. Symposium. Engaging patients and general public in health technology assessment: measuring and valuing health preferences. Health Technology Assessment International (iHTA) Annual Meeting, Tokyo, Japan. May 10-14, 2016.
3. (symposium) **Pickard AS**, Xie F, Pullenayegum E, Johnson J. Symposium. Engaging patients and general public in health technology assessment: measuring and valuing health preferences. Health Technology Assessment International (iHTA) Annual Meeting, Tokyo, Japan. May 10-14, 2016. May 21-25.
4. (podium) Law E, Pickard A, Kazczynski A, **Pickard AS**. Validity of health preferences elicited from children: comparing choice blindness and stated preferences between children and adults. ISPOR 21st Annual International Meeting, May 21-25, 2016 at the Washington Hilton in Washington, DC, USA. 3:45-4:45pm, Monday.
5. (poster) Law E, Joo M, Mark, **Pickard AS**. An approach to evaluating the usefulness of supplementing the EQ-5D descriptive system in obstructive pulmonary disease. ISPOR 21st Annual International Meeting, May 21-25, 2016 at the Washington Hilton in Washington, DC, USA. 3:45-7:45pm, Monday.
6. (podium) Jalundhwala YJ, **Pickard AS**. Psychological profiles of attitudes about health: does it make a difference to the self-rating of health and life satisfaction? International Society for Quality of Life Research, 22th Annual Conference, Vancouver, Canada. October 15-18, 2015. [Qual Life Res (2015)]
7. (poster) Jalundhwala YJ, **Pickard AS**. Performance of EQ-5D-5L in a large community-based survey. International Society for Quality of Life Research, 22th Annual Conference, Vancouver, Canada. October 15-18, 2015. [Qual Life Res (2015)]
8. (poster) Jalundhwala YJ, Sarah SL, Rondelli D, Law EH, **Pickard AS**. Improvement in HRQL for sickle cell disease patients treated with chemotherapy-free allogenic hematopoietic stem-cell transplantation: a pilot study. ISPOR international meeting, Philadelphia, USA. May 28-22, 2015. [Value Health (2015)]
9. (podium) Costa D, King MT, Aaronson N, Brazier JE, Cella D, Grimison P, Janda M, McTaggart-Cowan H, **Pickard AS**, Arbuckle R. The development of cancer-specific multi-attribute utility instruments from the EORTC QLQ-C30 and FACT-G. International Society for Quality of Life Research, 21th Annual Conference, Berlin, Germany. October 15-18, 2014. [Qual Life Res (2014) 23:29]
10. (podium) Norman R, King MT, Costa D, Aaronson N, Cella D, Fayers P, Kemmler G, **Pickard AS**, Street D, Velikova G, Young T, Viney R on behalf of the MAUCa Consortium. Valuing a utility

instrument derived from the EORTC QLQ-C30 (QLU-C10D): feasibility and respondent preference for presentation of 10 domains in a discrete choice experiment (DCE). International Society for Quality of Life Research, 21th Annual Conference, Berlin, Germany. October 15-18, 2014. [Qual Life Res (2014) 23:29]

11. (podium) Norman R, King MT, Costa D, Aaronson N, Cella D, Fayers P, Kemmler G, **Pickard AS**, Street D, Velikova G, Young T, Viney R on behalf of the MAUCa Consortium. Importance vs severity in the development of utility-based measures of health. International Society for Quality of Life Research, 21th Annual Conference, Berlin, Germany. October 15-18, 2014.
12. (poster) Golicki D, Janssen B, **Pickard AS**. Responsiveness of the EQ-5D-5L with stroke. International Society for Quality of Life Research, 21th Annual Conference, Berlin, Germany. October 15-18, 2014. [Qual Life Res (2014) 2:71]
13. (poster) Lin FJ, Lee TA, Joo M, **Pickard AS**. Inhaled anticholinergic medications and risk of urinary retention. ISPOR Asia Pacific conference. Beijing, China. Sept 6-8, 2014.
14. (poster) Cheng WH, Rash C, Patel P, Gratie D, Bathija S, Pickard AS, Berbaum M, et al. Impact of target specific oral anticoagulants on quality of life. ISPOR annual meeting, Montreal, Quebec, May 29-June 4, 2014. [Value in Health 17 (2014):A10].
15. (workshop) Xie F, **Pickard AS**, Kind P. Incorporating Patient-Reported Outcome Measures in Reimbursement Decision-Making: Measuring and Valuing Health Using the EuroQol-5 Dimension. 25th Annual Meeting, Canadian Agency for Drug and Technologies in Health (CADTH), April 5-7, 2014. .
16. (poster) Jiang R, Ursan I, Pickard EM, Lee TA, Ng D, **Pickard AS**. "Emergence of BCR-ABL1 Kinase Domain Mutations Associated with Newly Diagnosed Chronic Myeloid Leukemia: A Meta-Analysis of Clinical Trials of Tyrosine Kinase Inhibitors" AMCP, Tampa, Florida April 1-4, 2014.
17. (poster) **Pickard AS**, Lee TA, Mody S, Durkin M. "A Comparison of Dosing Patterns and Pharmacy Costs of Three Commonly Prescribed Oral Long-Acting Opioids: Tapentadol ER, Oxycodone CR, and Oxymorphone ER " AMCP, Tampa, Florida April 1-4, 2014.
18. (oral) Krabbe PFM, Devlin N, Stolk E, Shah K, Oppe M, van Hout B, Quik EH, **Pickard S**, Xie F. Multinational consistency of a discrete choice model in quantifying health states for the extended 5-level EQ-5D. ISPOR 16th Annual European Congress, Dublin, Ireland, Nov 2-6, 2013 [Value in Health 2014; 16(7):A326]
19. (symposium) **Pickard AS**, Kind P, Xie F. New Developments in Valuing Health: Directions for the EQ-5D. International Society for Quality of Life Research, 20th Annual Conference, Miami, Florida, USA. October 9-13, 2013.
20. (Oral) Craig BM, Reeve BB, Brown PM, Cella D, Hays RD, Lipscomb J, **Pickard AS**, Revicki DA. Valuation of Health Outcomes Measured Using the PROMIS-29, Conjoint Analysis in Healthcare, Dana Point, California, USA. October 2013; 20th Annual Conference, Miami, Florida, USA. October 9-13, 2013 [Qual Life Res 2013: 22(1):28]
21. (poster) Lin FJ, **Pickard AS**. Preferences for EQ-5D health states among patients undergoing knee replacement surgery. International Society for Quality of Life Research, 20th Annual Conference, Miami, Florida, USA. October 9-13, 2013. [Qual Life Res 2013: 22(1): 137.]
22. (oral) Cheng W-H, Patel H, Lee WJ, Lin FJ, **Pickard AS**. The Effect of Baseline Patient Characteristics on Outcomes of Varicose Vein Surgery. International Society for Quality of Life Research, 20th Annual Conference, Miami, Florida, USA. October 9-13, 2013. [Qual Life Res 2013: 22(1): 137]
23. (oral) Jalundhwala Y, Dang J, Gor D, Lin FJ, **Pickard AS**. Using Baseline Patient Self-Rating of Health to Predict the Outcomes of Hip Replacement Surgery. International Society for Quality of

Life Research, 20th Annual Conference, Miami, Florida, USA. October 9-13, 2013. [Qual Life Res 2013: 22(1): 137]

24. (oral) Craig BM, Reeve BB, Brown PM, Cella D, Hays RD, Lipscomb J, **Pickard AS**, Revicki DA. Valuation of Health Outcomes Measured Using the PROMIS-29. International Society for Quality of Life Research, 20th Annual Conference, Miami, Florida, USA. October 9-13, 2013. [Qual Life Res 2013: 22(1): 137]
25. (poster) Lin FJ, **Pickard AS**, Xie F. Are Canadians different from Americans in stated preferences for health? Valuing EQ-5D-5L Health states using discrete choice experiments. 18th ISPOR Annual International Meeting, New Orleans, LA. May 18-21, 2013.
26. (poster) **Pickard AS**, Lee TA, Mody S, Durkin M. A Comparison of the Daily Average Consumption (DACON) and Pharmacy Costs of Three Commonly Prescribed Oral Long-Acting Opioids: Tapentadol ER, Oxycodone CR, and Oxymorphone ER. Pain Week, Las Vegas, Sept 4-7, 2013.
27. (poster) **Pickard AS**, Lin FJ, Lee TA, Sharma G, Au DH, McBurnie MA, Carson SS, Lindenauer PK, Mularski RA, Naureckas ET, Vollmer WM, Henderson AG, Krishnan JA, on behalf of the CONCERT Consortium. Evaluation of the Functional Assessment of the Chronic Illness Therapy (FACIT)-Dyspnea short form in chronic obstructive pulmonary disease. American Thoracic Society International Conference, Philadelphia, PA. May 18-21, 2013.
28. (poster) **Pickard AS**, Lee TA, Lin FJ, Au DH, McBurnie MA, Carson SS, Lindenauer PK, Mularski RA, Naureckas ET, Vollmer WM, Henderson AG, Krishnan JA, on behalf of the CONCERT Consortium. Assessment of health-related quality of life using EQ5D-5L in patients with chronic obstructive pulmonary disease (COPD): experience in the CONCERT cohort. American Thoracic Society International Conference, Philadelphia, PA. May 18-21, 2013.
29. (poster) **Pickard AS**, Lee TA, Lin FJ, Au DH, McBurnie MA, Carson SS, Lindenauer PK, Mularski RA, Naureckas ET, Vollmer WM, Henderson AG, Krishnan JA, on behalf of the CONCERT Consortium. Measuring health using the Patient Reported Outcomes Measurement Information System (PROMIS43) in chronic obstructive pulmonary disease (COPD): experience in the CONCERT cohort. American Thoracic Society International Conference, Philadelphia, PA. May 18-21, 2013.
30. (oral presentation) Krabbe PFM, Devlin N, Stolk E, Shah K, Oppe M, van Hout B, **Pickard S**, Xie F. Evidence from four countries on the validity of the discrete choice model in quantifying health-states for the new EQ-5D-5L. ISOQOL 19th Annual Conference, Budapest, Hungary, Oct 24-28, 2012. Qual Life Res (2012)21:12.
31. (poster) Lin FJ, Samp JC, Munoz AR, Wong PS, **Pickard AS**. Using the PROMs data to understand and interpret changes in EQ-5D scores. ISOQOL 19th Annual Conference, Budapest, Hungary, Oct 24-28, 2012. Qual Life Res (2012)21:116.
32. (poster) King MT, Costa D, Aaronson N, Brazier JE, Cella D, Fayers P, Peacock S, **Pickard AS**, Rowens D, Velikova G, Young T, on behalf of the MAUCa Consortium. The development of an internationally valid cancer specific multi-attribute utility instrument (MAUI) from the EORTC core questionnaire, QLQ-C30. ISPOR 17th Annual International Meeting, Washington DC, USA. June 2-6, 2012.
33. (poster) **Pickard AS**, Ray S, Ganguli A. Utilities in 6 types of cancer. ISPOR 17th Annual International Meeting, Washington DC, USA. June 2-6, 2012.
34. (poster) Lin FJ, Wang PS, Lee TA, **Pickard AS**. Evaluation of Changes In Guidelines For Medication Management Of Stable Chronic Obstructive Pulmonary Disease (COPD) #2978. American Thoracic Society International Conference, San Francisco, CA, USA. May 22, 2012.

35. (poster) Solem CT, Gu N, **Pickard AS**. Identification of disease for EQ-5D bolt-on item development: an empirical approach. ISPOR 14th Annual European Congress, Madrid, Spain. November 8, 2011.
36. (oral presentation) Jalundhwala YJ, Shaw JW, **Pickard AS**, Walton SM. Health State Selection in EQ-5D Valuation Studies: Impact on Logical Inconsistencies and Predictive Accuracy. International Society for Quality of Life Research (ISOQOL) 18th Annual Conference. Denver, Colorado, USA, October 26-29, 2011. [*Finalist for Student Oral Presentation Award.](#)
37. (oral presentation) Shaw JW, **Pickard AS**, Cheng W. Dealing with Influential Observations in Analyses of EQ-5D Index Scores: A Comparative Evaluation of Robust Regression Estimators. International Society for Quality of Life Research (ISOQOL) 18th Annual Conference. Denver, Colorado, USA, October 26-29, 2011.
38. (oral presentation) Tawk R, **Pickard AS**, Shaw JW. Effect of chronic condition on the valuation of hypothetical EQ-5D health states. Society for Medical Decision Making, Chicago, IL, October 22 - 26, 2011.
39. (oral presentation) Lau D, Coon C, Chang CH, **Pickard AS**. Development of a Measure of Informal Caregiving Skills in Effective Medication Management for Hospice Patients (CG-SEMM): Interim Results" has been selected for Oral presentation during the 139th APHA Annual Meeting, Washington, DC, October 29 - November 2, 2011.
40. (oral presentation) Costa D, King M, Aaronson N, Cella D, Brazier JE, Fayers P, Pallant JS, Peacock S, **Pickard S**, Rowen D, Velikova G, Young T. Adaptation of a method for developing a preference-based measure from a descriptive health-related quality of life measure (HRQOL): a confirmatory versus exploratory approach for the cancer-specific QLQ-C30. International Society for Quality of Life Research (ISOQOL) 18th Annual Conference. Denver, Colorado, USA, October 26-29, 2011.
41. (poster) **Pickard AS**, Cella D, Duh MS, Guerin A, Mishagina N, Antràs L, Neary MP, McCann L, Hodge R, Sternberg CN. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomized phase III trial. ASCO 2011, June 4-6, Chicago IL, [J Clin Oncol 29: 2011 (suppl; abstr 9096)].
42. (poster) Yang YJ, Lee TA, **Pickard AS**. Comparison of clinical and patient-reported outcome measures in COPD. ISPOR 16th Annual International Meeting, Baltimore, MD, USA. May 2011.
43. (poster) **Pickard AS**, Ray S, Ganguli A, Cella D. Estimating utility in cancer: a comparison of EQ-5D and FACT-based algorithms. ISPOR 16th Annual International Meeting, Baltimore, MD, USA. May 2011.
44. (poster) Campbell C, Schumock GT, **Pickard AS**. FDA regulations and antidepressant utilization. ISPOR 16th Annual International Meeting, Baltimore, MD, USA. May 2011.
45. (workshop) Janssen MF, Van Hout B, Kind P, **Pickard AS**. Development of Interim Value Sets for the New 5 Level EQ-5d Descriptive System. ISPOR 13th Annual European Congress, Prague, Czech Republic, Nov 6-9, 2010.
46. (poster*) Shaw JW, Zhan L, Oppe M, **Pickard AS**. Multinational Evaluation of Conditional Median Models of EQ-5D Health State Preferences. International Society for Quality of Life Research Annual Meeting, London, UK, Oct 27-30, 2010. [*2010 Best Policy Research Poster of the Year.](#)
47. (poster) Shaw JW, Luo X, **Pickard AS**, Walton SM. Efficiency of estimation with the US population median-based EQ-5D index: findings from the MEPS. International Society for Quality of Life Research Annual Meeting, London, UK, Oct 27-30, 2010.

48. (podium*) Wilke CT, Lee TA, Lambert BL, Walton S, Joo MJ, **Pickard AS**. Sensitivity of Hazard Estimates to Exposure Definitions: a simulation study. 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton, United Kingdom August 19-22, 2010. *2010 IPSE Stanley A. Edlavitch Award for the Best Student Abstract
49. (podium) Wilke CT, Lin FJ, Lee TA, Lambert BL, Joo MJ, **Pickard AS**. Variability in Measurement of Medication Exposure In Pharmacoepidemiologic Studies Of COPD. 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton, United Kingdom August 19-22, 2010.
50. (poster) Jolly M, **Pickard AS**, McElhone K, Lee ST, Mikolaitis RA, Rodby R, Sequeira W, Utset TO, Nicassio P, Ishimori ML, Wallace DJ, Weisman MH, Block JA. Disease Specific Patient Reported Outcome Benchmarks for US Lupus Patients: LupusPRO and LupusQoL-US. 9th International Congress on Systemic Lupus Erythematosus in Vancouver, British Columbia, Canada, June 24 – 27, 2010.
51. (poster) Jolly M, **Pickard AS**, Cash TF, Block JA. Use of Body Image Lupus Screening (BILS) tool in Systemic Lupus Erythematosus: What can we learn? 9th International Congress on Systemic Lupus Erythematosus in Vancouver, British Columbia, Canada, June 24 – 27, 2010.
52. (poster) Jolly M, Fogg L, **Pickard AS**, Cash TF, Block JA. Body Image directly affects health outcomes in Systemic Lupus Erythematosus. 9th International Congress on Systemic Lupus Erythematosus in Vancouver, British Columbia, Canada, June 24 – 27, 2010.
53. (poster) Jolly M, Mikolaitis RA, Sequeira W, **AS Pickard**, Fogg L, Cash TF, Block JA. Body Image in Patients With Systemic Lupus Erythematosus. 9th International Congress on Systemic Lupus Erythematosus in Vancouver, British Columbia, Canada, June 24 – 27, 2010.
54. (poster) Jolly M, **Pickard AS**, Mikolaitis RA, Block JA, Moldovan I, Katsaros E, Ishimori ML, Wallace DJ, Weisman MH, Nicassio P. Preliminary Validation of Spanish Version of The LupusPRO V1.4. 9th International Congress on Systemic Lupus Erythematosus in Vancouver, British Columbia, Canada, June 24 – 27, 2010.
55. (poster) Jolly M, Dua A, Mikolaitis RA, **Pickard AS**, Sequeira W, Block JA. Does Systemic Lupus Erythematosus affect desire for Intimacy? 9th International Congress on Systemic Lupus Erythematosus in Vancouver, British Columbia, Canada, June 24 – 27, 2010.
56. (poster) Jolly M, **Pickard AS**, Mikolaitis RA, Wilke C, Rodby R, Fogg L, Sequeira W, Utset TO, Cash TF, Moldovan I, Katsaros E, Nicassio P, Ishimori ML, Wallace DJ, Weisman MH, Block JA. The LupusPRO©: A disease-specific patient reported outcome measure for systemic lupus erythematosus in the U.S.A. 9th International Congress on Systemic Lupus Erythematosus in Vancouver, British Columbia, Canada, June 24 – 27, 2010.
57. (poster) Jolly M, **Pickard AS**, Wilke C, Mikolaitis RA, Cash TF, Block JA. A Brief Body Image Screening Tool for Systemic Lupus Erythematosus. 9th International Congress on Systemic Lupus Erythematosus in Vancouver, British Columbia, Canada, June 24 – 27, 2010.
58. (poster) Jolly M, **Pickard AS**, The LS, Mcelhone K, Wilke C, Mikolaitis RA, Fogg L, Block JA. Health Related Quality of Life using the LupusQoL-US tool© among Systemic Lupus Erythematosus patients. 9th International Congress on Systemic Lupus Erythematosus in Vancouver, British Columbia, Canada June 24 – 27, 2010.
59. (poster) Jalundhwala Y, Shaw JW, **Pickard AS**, Walton S, Busschbach J. Impact of severity differences on logical inconsistencies in values for EQ-5D health states. 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, GA, May 15-19, 2010. (poster presentation) [Value in Health. 2010 May; 13(3): A184, Abstract PIH19.]

60. (podium) Lee TA, Wilke CT, Joo M, Krishnan J, Schumock GT, **Pickard AS**. Risk of Stroke Associated with Ipratropium and Tiotropium Use in Patients with COPD. 2010 American Thoracic Society (ATS) International Conference in New Orleans, Louisiana, May 19, 2010.
61. (poster) Lin HW, **Pickard AS**, Karabatsos G, Mahady GB, Crawford SY, Popovich NG. Validating Likert-type measures using nonparametric and parametric item response theory. ISPOR 14th Annual International Conference, Orlando, FL, May 16-20, 2009. [*Value in Health* 2009 May; 12(3): A120]
62. (poster) Liu XQ, Walton SM, Crawford SY, **Pickard AS**. The impact of medicare part D on health care utilization and health outcomes for medicare beneficiaries without previous drug coverage. ISPOR 14th Annual International Conference, Orlando, FL, May 16-20, 2009. [*Value in Health* 2009 May;12(3): A170]
63. (podium) Lee TA, Wilke CT, Joo M, Stroupe KT, Krishnan JA, Schumock GT, **Pickard AS**. Outcomes associated with tiotropium use in COPD patients. ISPOR 14th Annual International Conference, Orlando, FL, May 16-20, 2009. [*Value in Health* 2009 May;12(3): A19]
64. (poster) Wilke CT, **Pickard AS**. Test-retest reliability of the EQ-5D visual analog scale across populations and conditions. ISPOR 14th Annual International Conference, Orlando, FL, May 16-20, 2009. [*Value in Health* 2009 May;12(3): A30]
65. (poster) Lee TA, Wilke CT, Joo M, Stroupe KT, Krishnan JA, Schumock GT, **Pickard AS**. Comparative effectiveness of ipratropium in COPD patients. ISPOR 14th Annual International Conference, Orlando, FL, May 16-20, 2009. [*Value in Health* 2009 May;12(3): A121]
66. (poster) Wilke CT, Young GA, Cooper DL, **Pickard AS**. Feasibility of daily diaries with QoL assessment in congenital hemophilia patients with alloantibody inhibitors. ISPOR 14th Annual International Conference, Orlando, FL, May 16-20, 2009. [*Value in Health* 2009 May;12(3): A137]
67. (poster) Schiff G, Duhig J, Edison M, Galanter W, Koronkowski M, Lambert BL, Lodolce A, **Pickard AS**, Wilke CT. Drug Formulary Culture Survey: Measuring the Temperature of Clinicians' Boiling Blood. Society of General Internal Medicine 32nd Annual Meeting, Miami Beach, FL, May 13-16, 2009.
68. (podium) Duhig J, Edison M, Galanter W, Koronkowski M, Lambert BL, Lodolce A, **Pickard AS**, Wilke CT, Schiff G. Conceptual issues in the development of a measure of formulary culture. ISPOR, May 16-20, 2009, Orlando, Florida, USA. [*Value in Health* 12(3): A9]
69. (poster) Snedecor S, Botteman M, **Pickard AS**. Economic outcomes of co-treatment of insomnia and major depressive disorder (MDD) with eszopiclone and fluoxetine treatment alone, ISPOR 11th Annual European Congress, Athens, Greece, November 8-11, 2008.
70. (podium) Lin HW, **Pickard AS**, Karabatsos G, Mahady GB, Crawford SY, Popovich NG., Development and validation of a measure to assess general and herbal and dietary supplement-specific patient counseling by pharmacists. American Association of Colleges of Pharmacy (AACP), July 19-23, Chicago, 2008.
71. (Award nominated podium) Wilke CT, **Pickard AS**, Lee TA, Walton SM, Mook J, Kohlmann T. Utility Weighted compared to unweighted EQ-5D and HUI3 summary scores: implications for statistical inference. Midwest Social and Administrative Pharmacy Conference, Chicago, IL, July 23-25, 2008.
72. (podium) Lin HW, **Pickard AS**, Karabatsos G, Mahady GB, Crawford SY, Popovich NG. The impact of pharmacists' knowledge, attitude and self-efficacy toward their performance of patient counseling on herbs and dietary supplements. Midwest social and administrative pharmacy conference, Chicago, IL , July 23-25, 2008.

73. (discussion poster) **Pickard AS**, Shaw JW, Lin HW, Trask PC, Aaronson N, Lee TA, Cella D. A patient-based utility measure of health for clinical trials of cancer therapy. Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, Illinois. [J Clin Oncol (Meeting Abstracts) 2008 26: 6529.]
74. (podium) Duh MS, **Pickard AS**, Chen L, Antras L, Cella D, Neary M, O'Brien M. Evaluation of impact of oral topotecan on health-related quality of life in relapsed small cell lung cancer (PR4). ISPOR, May 3-7, 2008, Sheraton Centre Toronto, Toronto, Ontario, Canada. [*Value in Health*]
75. (poster) Lin HW, **Pickard AS**, Wittenberg R, Tsai HH, Lin SJ, Shaw JW, Herb/Dietary Supplement and Prescription Drug Use Trends among US Adults, 1999-2004. ISPOR, May 3-7, 2008, Sheraton Centre Toronto, Toronto, Ontario, Canada. [*Value in Health*]
76. (poster) Lee WC, **Pickard S**, Wilke C, Joshi AV, Yeh YC, Wang Q, Pashos CL. Economic impact of stroke-related comorbid conditions on the treatment of stroke: an analysis of Medicare beneficiaries in the United States ISPOR, May 3-7, 2008, Toronto, Ontario, Canada. [*Value in Health*]
77. (podium) Lin HW, **Pickard AS**, Karabatsos G, Mahady GB, Crawford SY, Popovich NG, Validating a Survey Instrument Using Nonparametric Item Response Theory – Application of Kernel Regression. ISPOR, May 3-7, 2008, Toronto, Ontario, Canada. [*Value in Health*]
78. (podium) Shaw JW, **Pickard AS**, Lin HW, Cella D, Trask PC. Evaluation of a Theory Of Global Health Preference Formation. ISPOR, May 3-7, 2008, Toronto, Ontario, Canada. [*Value in Health*]
79. (poster) Wilke CT, **Pickard AS**, Feeny DH, Johnson JA. Responsiveness of Proxy-Rated Preference-Based Measures of Health Related Quality of Life. ISPOR 13th Annual International Conference, Toronto ON Canada, May 5-7, 2008 [*Value in Health*].
80. (podium) Lin HW, **Pickard AS**, Mahady GB, Popovich NG, Identification and creation of knowledge-based content and validation of a measure to assess pharmacist knowledge of herbal and dietary supplements: preliminary study. Annual Meeting of American Pharmacist Association, San Diego, CA, March 16, 2008.
81. (podium) Lee TA, **Pickard AS**, Bartle B, Weiss KB. "Medication Safety in COPD Patients: The Risk of Respiratory and Cardiovascular Deaths Associated with Treatment in Veterans with COPD." VA Health Service Research and Development 2008 National Meeting, Baltimore, MD, February 2008.
82. (poster) Wilke CT, **Pickard AS**, Walton SW, Lee TA. Utility weighted compared to unweighted EQ-5D and HUI3 summary scores: implications of statistical inference. ISPOR 10th Annual European Congress, Dublin Ireland, 20-23 October 2007.
83. (poster) Wilke CT, Jung E, Lee TA, **Pickard AS**. EQ-5D utilities associated with levels of COPD severity: a meta-analytic approach. ISPOR 10th Annual European Congress, Dublin Ireland, 20-23 October 2007.
84. (poster) **Pickard AS**, Neary M, Cella D. Estimation of important differences in EQ-5D VAS scores in cancer. ISPOR 10th Annual European Congress, Dublin Ireland, 20-23 October 2007.
85. (poster) Snedecor S, Botteman M, **Pickard AS**. Comparison of four preference-based SF-36/SF-12 algorithms to evaluate the cost-effectiveness of treatment for primary insomnia with eszopiclone. ISPOR 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007.
86. (poster) Snedecor S, Botteman M, **Pickard AS**. An analytical model to predict the cost-effectiveness of long-term eszopiclone for the treatment of primary insomnia. ISPOR 10th Annual European Congress, Dublin Ireland, 20-23 October 2007.

87. (poster) Jolly M, **Pickard AS**, Wilke C, Lin HW, Khandelwal S, Rodby R, Block JA. Modification and Preliminary Validation of the Lupus Quality of Life (LupusQol) index: US Version©. Conference for the International society for quality of life research (ISOQOL), Toronto, Canada, Oct 10-13th, 2007. [Quality of Life Research].
88. (poster) Jolly M, **Pickard AS**, Mikolaitis R, Wilke C, Khandelwal S, Rodby R, Block JA. Disease Activity, Body Image and Health Status in Lupus. American College of Rheumatology Annual Scientific Meeting, Boston, MA, November 6-11, 2007 [Arthritis and Rheumatism].
89. (poster) Jolly M, **Pickard AS**, Wilke C, Khandelwal S, Rodby R, Fogg L, Block JA. Satisfaction with care and health status in Lupus. American College of Rheumatology Annual Scientific Meeting, Boston, MA, November 6-11, 2007 [Arthritis and Rheumatism].
90. (podium) Wilke C, Jolly M, Block JA, Khandelwal S, Rodby R, **Pickard AS**. Ability of SF-36 and EQ-5D to discriminate among disease activity levels in Lupus. ISPOR 12th annual international conference, Arlington VA, May 18-23rd, 2007. [Value in Health 10 (3) A15].
91. (poster) Chen L, Antras L, Duh MS, **Pickard AS**, Cella D, Neary M, O'Brien MER. Assessment of health status in trial of oral topotecan plus best supportive care versus best supportive care alone in small cell lung cancer. International Society for Quality of Life Research (ISOQOL) conference on Patient Reported Outcomes in Clinical Practice, Budapest, Hungary, June 24-26th, 2007.
92. (poster) **Pickard AS**, Neary M, Cella D. Estimation of meaningful differences in EQ-5D index-based scores in cancer. International Society for Quality of Life Research (ISOQOL) conference on Patient Reported Outcomes in Clinical Practice, Budapest, Hungary, June 24-26th, 2007.
93. (poster) **Pickard AS**, Lin HW, De Leon MC, Rosenbloom S, Cella D. Comparison of impact of eleven types of advanced cancer on quality of life. ISPOR 12th annual international conference, Arlington VA, May 18-23rd, 2007.
94. (poster) Lee TA, **Pickard AS**, Bartle B, Schumock GT, Weiss KB. Increased risk of mortality associated with use of ipratropium and theophylline in COPD patients. American Thoracic Society International Conference, San Francisco, CA, May 2007.
95. (poster) Lee TA, **Pickard AS**, Bartle B, Schumock GT, Weiss KB. "Outcomes associated with theophylline use in COPD patients." American Thoracic Society International Conference, San Francisco, CA, May 2007.
96. (poster) Wilke C, Jolly M, Khandelwal S, Rodby R, Block JA, **Pickard AS**. Understanding Limitations of Patient Reported Clinical Outcomes in Lupus. ISPOR 12th annual international conference, Arlington VA, May 18-23rd, 2007. [Value in Health 10 (3) A92]
97. (talking poster) **Pickard AS**, Bennett CL, Lin H-W, Knight SJ, Wu Z, Shih V, Sharifi R. Significant relationships between biological/clinical and self-reported measures of health in prostate cancer. American Urology Association Meeting, Anaheim CA, May 19-24th, 2007.
98. (podium) DeLeon MC, **Pickard AS**, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5 level version: evidence from a US-based multicenter study of cancer patients. ISOQOL conference, Lisbon, Portugal, Oct 11-14, 2006.
99. (podium) **Pickard AS**, Kohlmann T, Janssen MF, Bonsel G, Cella D, Rosenbloom S. Come together: development of a valuation crosswalk between the 3 level and 5 level EQ-5D using item response theory. ISOQOL conference, Lisbon, Portugal, Oct 11-14, 2006.
100. (poster) **Pickard AS**, Lin HW, Knight SJ, Hung S-Y, Chang C-H, Sharifi R, Bennett CL. Proxy rating of HRQL using EQ-5D and EORTC QLQ: Does proxy viewpoint affect assessment? ISOQOL conference, Lisbon, Portugal, Oct 11-14, 2006.

101. (poster) Wilke C, Lin HW, **Pickard AS**. Impact of cancer on HRQL: evidence using the EQ-5D. Midwest Pharmacy Administration conference, Minneapolis, MN, July 27-29th, 2006 [Research in Social and Administrative Pharmacy].
102. (poster) Lin HW, **Pickard AS**, Ferrans C. Use of the Rasch rating scale to inform a short-form version of the quality of life index. Midwest Pharmacy Administration conference, Minneapolis, MN, July 27-29th, 2006 [Research in Social and Administrative Pharmacy].
103. (podium) Jung E, **Pickard AS**, Lee TA, Bartle B. Veterans with COPD: causes of mortality and medication use prior to death. Midwest Pharmacy Administration conference, Minneapolis, MN, July 27-29th, 2006 [Research in Social and Administrative Pharmacy].
104. (poster) Hung SY, **Pickard AS**, Witt WP, Lambert BL. Impact of caregiver depression and pain on proxy assessments of patient health-related quality of life after stroke. Midwest Pharmacy Administration conference, Minneapolis, MN, July 27-29th, 2006 [Research in Social and Administrative Pharmacy].
105. (publication only) Witt WP, **Pickard AS**, Kuzel T, McDade T, Perry S, Hung S, Zagory J, Lin H, Costello S, Colella K, and Bennett CL. Relationship between biological and self-reported measures of stress among informal caregivers of patients with prostate cancer. ASCO Meeting 2006. [Journal of Clinical Oncology. 2006; 24(18S):18506]
106. (poster) Sundy JS, Schumacher HR, Becker MA, Edwards NL, Hatoum H, **Pickard AS**, Waltrip III RW. Quality of life in patients with treatment-failure gout. EULAR Conference, June 2006 [Ann Rheum Dis 2006;65 (Suppl II):271.]
107. (poster) Dobrez D, **Pickard AS**, Cella D, Lai JS, Nickolov A. Estimation of patient preference-based utility weights from the FACT-G. ISPOR, Philadelphia, PA, May 20-24, 2006.
108. (poster) Lee TA, **Pickard AS**, Barlett B, Weiss K. Prescription for longer life: a diagnosis of osteoarthritis? ISPOR, Philadelphia, PA, May 20-24, 2006.
109. (poster) Wang Z, Walton S, Lee TA, **Pickard AS**. Patient adherence with antidiabetic, antihypertensive, and lipid-powering medications: evaluation of veteran with type 2 diabetes. ISPOR, Philadelphia, May 20-24, 2006.
110. (poster) **Pickard AS**, Hung SY. Clinical pharmacy services: an update on evidence of impact on health-related quality of life. ACCP Spring Forum, Monterey CA, April 9-12th, 2006.
111. (poster) **Pickard AS**, Bauman JL. An inquiry into research interests and support needs of clinical pharmacy faculty. ACCP Spring Forum, Monterey CA, April 9-12th, 2006.
112. (poster) Hatoum HT, **Pickard AS**. Cost-utility analysis. Oxandrolone versus no treatment for cancer-related weight loss. 1st Annual Chicago Supportive Oncology Conference. October 6-8, 2005. Chicago, IL.
113. (podium) **Pickard AS**, Knight SJ, Hung S-Y, Chang C-H, Sharifi R, Bennett CL. The importance of proxy perspective in HRQL assessment: preliminary results in prostate cancer. International Society of Quality of Life Research, San Francisco, Oct 19-22, 2005. [Quality of Life Research 2005;14(9):2008.]
114. (podium) Rashidi AA, Richardson K, **Pickard AS**, Marra CA. Use of bland-Altman plots to assess agreement for proxy-patient HRQL assessments: a new method that adjusts for chance agreement. International Society of Quality of Life Research, San Francisco, Oct 19-22, 2005. (awarded best presentation (oral)) [Quality of Life Research 2005;14(9):2018.]
115. (poster) McCaffrey KR, Patel W, Rosen F, Carson KR, Okano GJ, Auto H, Sharma R, Argiris A, **Pickard AS**, Schumock GT, Bennett C. Inpatient and Outpatient Costs for Head and Neck (HNC)

and Non-Small Cell Lung Cancer (NSCLC) Patients with Oral Mucositis (OM) and/or Esophagitis Who Undergo Chemoradiotherapy. American Society of TASTRO, Denver, Colorado, Oct 16-20th 2005.

116. (podium) **Pickard, AS**, Wang Z, Walton SM, Lee TA. Choosing between SF-12/SF-36 preference-based algorithms for cost-utility analysis. (oral podium) International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Washington, D.C., May 15-18, 2005. [*Value in Health* 2005;8(3):240]
117. (podium) Dalal MR, **Pickard AS**, Lin SW, Hedeker DL. Support for Classification of Depression Outcomes into Longitudinal Patterns: evidence from a population-based study of the elderly. (oral podium) International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Washington, D.C., May 15-18, 2005. [*Value in Health* 2005;8(3):257]
118. (poster) Carson KR, McCaffrey KR, Sharma R, Okano GJ, Argiris A, **Pickard AS**, Schumock GT, Bennett CL. Cost of hospitalization for head and neck or non-small cell lung cancer (NSCLC) patients with oral mucositis and/or esophagitis who undergo radiochemotherapy. American Society of Clinical Oncology Annual Meeting, Orlando June 2-6th, 2005. Abstract #8089.
119. (poster) McCaffrey KR, Carson KR, Kutikova L, Fisher M, **Pickard AS**, Schumock G, Bowman L, Bennett CL. Developing National Estimates of the Out-of-Pocket Costs of Cancer: The Importance of Including Patients with Lymphoma. American Society of Hematology, San Diego, December 10-12th 2004. [*Blood* 2004; 104:11: abstract #3138].
120. (podium) Ramsewak F, Schumock G, **Pickard AS**. Decision analysis of options for prevention of stress ulcer prophylaxis in critically ill patients. Second Biennial Conference of Health Science and Research, Focus in the Caribbean. Trinidad, Oct 12, 2004.
121. (poster) **Pickard AS**, McKoy J, McWilliams N, Utukuri S, Witt WP, Hung S-Y, Heckinger E, Bennett CB. A Novel Application of Disease State Management: Design and Evaluation of a DSM Program for Prostate Cancer Patients and Family Caregivers. Disease Management Association of America Conference, Orlando, Florida, Oct 20-23, 2004.
122. (poster) Powell EF, Fitzner KA, Bennett CL, **Pickard AS**, Schumock G, Hiliker P, McKoy JM. Compliance With Screening Recommendations and a Physician-Directed Intervention. Disease Management Association of American, Orlando, Florida, October 20-23, 2004.
123. (poster) Fitzner KA, Bennett CL, **Pickard AS**, Schumock G, Hiliker P, McKoy JM, Powell E. Cost-Effectiveness for a Physician-Directed Colorectal Study Intervention. Presented at DMAA, October 2004.
124. (poster) **Pickard AS**, Knight S. A conceptual framework for understanding differences in proxy perspectives. International Society of Quality of Life Research, Hong Kong, November 11-15, 2004. [*Quality of Life Research* 2004; 13(7):1584]
125. (poster) Hatoum HT, **Pickard AS**, Ottery F, Greenberg KA. A predictive model of hospitalization and potential cost savings associated with oxadrolone in cancer patients with IWL. Annual Meeting of the American College of Clinical Pharmacy, Dallas, Texas, October 26, 2004 (encore presentation). [*Pharmacotherapy* 2004;24(10):1454]
126. (poster) Golub RM, Knight S, **Pickard S**, Kramer K, Lyons EA, Arseven A, Wolf MS, Bennett CL. Problems measuring prostate-related utilities in low literacy patients. 40th annual meeting of American Society of Clinical Oncology (ASCO), New Orleans, June 2004. [*ASCO proceedings* 2004;23:548].
127. (publication only) Hatoum HT, **Pickard AS**, Ottery F. A Predictive Model of Hospitalization and Potential Cost Savings associated with Oxadrolone in Cancer Patients with Involuntary Weight

Loss. 40th annual meeting of American Society of Clinical Oncology (ASCO), New Orleans, June 2004. [ASCO proceedings 2004;23:789].

128. (poster) Arseven A, Wolf MS, Lyons EA, **Pickard AS**, Golub RM, Knight SJ, Kramer K, Colella K, Bennett CL. Shared decision-making for older, poor, newly diagnosed prostate cancer patients may not be possible. 40th annual meeting of American Society of Clinical Oncology (ASCO), New Orleans, June 2004. [ASCO proceedings 2004;23:538].
129. (poster) **Pickard AS**, Dalal M, Bushnell D. Depression in the general population and after stroke: a psychometric comparison using the CES-D Scale. ISPOR, Arlington, VA, May 12-15th 2004 [Value in Health 2004;7(3):285]
130. (poster) Dalal M, **Pickard AS**, Lin S-J. Out-of-pocket drug expenditures and patterns of depression in the elderly: a 5-year population-based study. ISPOR Conference, Arlington, VA, May 12-15th 2004 [Value in Health 2004;7(3):271]
131. (poster) Nutescu EA, **Pickard AS**, Blackburn JC, Wittkowsky AK, Ansell J, Schumock GT. Implications of Oral Direct Thrombin Inhibitors for Anticoagulation Clinics. American College of Clinical Pharmacy/European Society of Clinical Pharmacy (ACCP/ESCP) Conference, Paris, France. April 28-30, 2004.
132. (poster) Hatoum HT, **Pickard AS**, Ottery F. Use of the Patient-Generated Subjective Global Assessment (PG-SGA) to predict rate of hospitalization for cancer patient with involuntary weight loss (IWL): role for standardized assessment and early intervention. MD Anderson Symposium, Houston, Texas, February 16th 2004.
133. (podium) **Pickard AS**. A novel approach to assessing agreement between raters of multi-dimensional measures at the individual level using fuzzy set theory. International Society for Quality of Life Research, Prague, Czech Rep, Nov 12-15, 2003. [Quality of Life Research 2003; 12(7):749]
134. (poster) **Pickard AS**, Dalal M. Predictors of change in caregiver HRQL after stroke. Presented at International Society for Quality of Life Research, Prague, Czech Rep, Nov 12-15, 2003. [Quality of Life Research 2003; 12(7):853].
135. (poster) Park H, Schumock GT, **Pickard AS**, Akhras K. A systematic review of the relationship between microalbuminuria and cardiovascular events in patients with hypertension and diabetes. American College of Clinical Pharmacy, Spring Meeting, Palm Springs, CA, April 29, 2003. [Pharmacotherapy 2003;23(3):392]
136. (podium) **Pickard AS**, Johnson JA, Feeny DH. Responsiveness of the SF-36, HUI and EQ-5D in Stroke Qual Life Res 2002. Presented at International Society for Quality of Life Research Conference, Orlando, Florida, USA, Oct 30-Nov 2, 2002. [Quality of Life Research 2002; 12(7):853].
137. (podium) **Pickard AS**, Menon D. Extra patient considerations in evaluating restrictive drug reimbursement policy. Presented at the Canadian Association for Population Therapeutics Conference, Toronto, Ontario, April 14-16, 2002. [Canadian Journal of Clinical Pharmacology 2002 Vol 9(1):21]
138. (podium) **Pickard AS**, Johnson JA, Feeny DH, Carriere KC, Shuaib A. Agreement between self- and proxy assessment in stroke: a comparison of generic HRQL measures. Presented at International Society for Quality of Life Research, Amsterdam, the Netherlands, November 6-9th, 2001. [Quality of Life Research 2001;10(3):210].
139. (poster) **Pickard AS**, Weijnen ThJG, Niewenhuizen MGM, Johnson JA, de Charro FTh. A Comparison of Canadian and European VAS-Based valuations of EQ-5D health states. Presented

prescription drug monitoring programs in Illinois with the broader goal of reducing the use and abuse of opioids.

Pickard/Schumock (co-PIs) 01/15 – 01/18 1.2 calendar
PhRMA Foundation \$250,000
UIC Center of excellence for comparative effectiveness research education program
This 3-year grant is to design and implement a graduate program degree based program in comparative effectiveness research.

Pickard (PI) 07/15 – 06/17 0.5 calendar
Takeda \$161,000
Takeda-UIC 2-year fellowship in health economics and outcomes research
This is a 2-year fellowship funded by Takeda that provides training in health economics and outcomes research that includes onsite training at Takeda Pharmaceuticals International and coursework/research experience with faculty based in the Center for Pharmacoeconomics Research at the College of Pharmacy at UIC.

2014

Pickard (PI) 11/14 – 11/15 2.0 calendar
Pew Charitable Trust \$137,213
National assessment of state oversight of drug compounding
In this project, we will conduct a landscape analysis of state oversight of compounding practices, including a comparison of current state practices to best practices.

Pickard (PI) 06/14 – 06/15 1.0 calendar
EuroQol Group \$26,560
Understanding the relationship between health behaviors, attitudes and perceptions of HRQL using the EQ-5D
This project examines the whether perceptions of quality of life systematically differ by aspects of personality that relate to health attitudes and behaviors through different life stages.

Pickard (PI) 07/14 – 06/16 0.5 calendar
Takeda \$161,000
Takeda-UIC 2-year fellowship in health economics and outcomes research
This is a 2-year fellowship funded by Takeda that provides training in health economics and outcomes research that includes onsite training at Takeda Pharmaceuticals International and coursework/research experience with faculty based in the Center for Pharmacoeconomics Research at the College of Pharmacy at UIC.

Pickard (PI) 01/14 – 06/15 0 calendar
EuroQol Group \$28,220
Development of a HRQL data archive
This contract provides funding to support the development and maintenance of an EQ-5D data archive on behalf of the EuroQol group.

2013

Krishnan (PI) 08/13 – 07/16 0.5 calendar
PCORI \$1,973,706
PATient Navigator to rEduce Readmissions (PARTNER)
This UI Health led study will evaluate the effectiveness of Patient Navigators to reduce hospital readmissions. This research project focuses on developing and testing a program that combines proactive lay patient advocates from the community in which the patient lives (community health worker, CHW) together with a peer-led telephone information line to improve patient experience and reduce hospital readmissions.

Pickard (PI) 07/13 – 06/15 0.5 calendar
 Takeda \$164,000
Takeda-UIC 2-year fellowship in health economics and outcomes research
 This is a 2-year fellowship funded by Takeda that provides training in health economics and outcomes research that includes onsite training at Takeda Pharmaceuticals International and coursework/research experience with faculty based in the Center for Pharmacoeconomics Research at the College of Pharmacy at UIC.

Pickard (PI) 08/13 – 08/14 1.5 calendar
 Ariad Pharmaceuticals \$35,454
BCR-ABL-1 mutations conferring treatment resistance to tyrosine kinase inhibitors among patients with chronic myeloid leukemia
 The aim of this project is to use a meta-analytical approach to estimate the rate of (BCR-ABL-1-related) treatment resistance associated with TKIs in CML.

2012

Schumock (PI) 11/12 – 09/13 1.8 calendar
 FDA (Subcontract- Harvard University) \$249,000
Alternative Methods for Health Outcomes Validation
 While efforts are underway to conduct health outcomes of interest (HOI) algorithm validation against medical records within Mini-Sentinel, this process is very resource intensive, both in terms of time and money. There is a need to consider more cost-efficient approaches to validating algorithms used to identify HOIs in the Mini-Sentinel distributed data network. We propose to examine alternatives to medical record review, such as identifying databases that could be linked to MSDD for a given HOI.

Pickard (PI) 07/12 – 06/14 0 calendar
 Takeda \$128,814
Takeda-UIC 2-year fellowship in health economics and outcomes research
 This is a 2-year fellowship funded by Takeda that provides training in health economics and outcomes research that includes onsite training at Takeda Pharmaceuticals International and coursework/research experience with faculty based in the Center for Pharmacoeconomics Research at the College of Pharmacy at UIC.

Lambert (PI) 06/07 – 06/12 (1-year no cost extension) 0.6 calendar
 AHRQ CERT \$4,000,000
Optimizing medication-related decision making
 This study is part of the multi-study agenda of the UIC CERT that involves the development of a conceptual framework and a measure of the components that contribute to a culture of rational prescribing.

Craig (PI) 09/11 – 07/16 Consultant
 R01 CA160104-01 \$3,129,188
HRQoL Values for Cancer Survivors: Enhancing PROMIS Measures for CER
 This study aims to develop a multi-attribute health utility measure based upon items banks from the PROMIS, and to compare the HRQL values from the general population to the values of cancer survivor. I serve on the expert advisory panel.

2011

Pickard (PI) 03/11 – 09/12
 EuroQol Group \$98,000
Valuation of the EQ-5D-5L: United States arm of multi-country protocol
 The main aim of this study was to conduct a US-based pilot of newly developed techniques and software for health valuation for the EQ-5D-5L using a protocol standardized for international studies.

Pickard (PI) 07/11 – 06/13
 Takeda \$128,814 0 calendar (fellowship)
Takeda-UIC 2-year fellowship in health economics and outcomes research
 This is a 2-year fellowship funded by Takeda that provides training in health economics and outcomes research that includes onsite training at Takeda Pharmaceuticals International and coursework/research experience with faculty based in the Center for Pharmacoeconomics Research at the College of Pharmacy at UIC.

2010

King M (PI) 07/10 – 10/14
 Health and Medical Research Council (NHMRC)/Project Grants (Australia). 0 calendar
Development and valuation of cancer-specific multi-attribute health states for use in economic evaluation;
 This project led by University of Sydney researchers proposes to develop and value health states described by the EORTC-QLQ-C30 and FACT-G cancer specific measures of HRQL. I serve as part of the international consortium of experts who were designated as associate investigators.

Pickard (PI) 07/10 – 06/12
 Takeda \$128,814 0 calendar (fellowship)
Takeda-UIC 2-year fellowship in health economics and outcomes research
 This is a 2-year fellowship funded by Takeda that provides training in health economics and outcomes research that includes onsite training at Takeda Pharmaceuticals International and coursework/research experience with faculty based in the Center for Pharmacoeconomics Research at the College of Pharmacy at UIC.

Schumock (PI) 09/10 – 09/13
 AHRQ \$ --- 0 calendar
DEcIDE-2 Research Network.
 This is a center renewal from AHRQ that includes a master agreement where key personnel at the Chicago-Area DEcIDE center can compete for task order contracts issued by AHRQ that focus on research and program development relevant to the safety, effectiveness, efficiency and outcomes of health care items and services. I serve as co-deputy PI with David Meltzer (University of Chicago).

2009

Pickard (PI) 10/09 – 11/10
 Novartis \$102,736 1.8 calendar
Robustness of medication exposure definitions related to patterns of medication use for comparativeness effectiveness in COPD
 Summary: Purpose of research is to evaluate how patterns of medication switching affect the sensitivity of exposure definitions to choice of exposure window, including the downstream effect on exposure-outcomes associations in comparative effectiveness research.

Pickard (PI) 10/09 – 09/11
 Takeda \$127,812 0 calendar (fellowship)
Takeda-UIC 2-year fellowship in health economics and outcomes research
 This is a 2-year fellowship funded by Takeda that provides training in health economics and outcomes research that includes onsite training at Takeda Pharmaceuticals International and coursework/research experience with faculty based in the Center for Pharmacoeconomics Research at the College of Pharmacy at UIC.

Krishnan, Lee et al (multi-PI) 10/09 – 09/11
 NHLBI \$6,847,299 1.8 calendar
 1RC2HL101618
CONCERT-Clinical Effectiveness Research (CONCERT-CER)

The aim of this multi-institutional consortium of interdisciplinary investigators is to develop a research infrastructure that will accelerate the development and conduct of multi-center studies that are responsive to COPD CER priorities identified by stakeholders. My primary responsibility was selection, analysis and interpretation of outcome measures for the study.

Pickard (PI) 10/09 – 09/10 2.4 calendar
 Edward Hines Jr VA Hospital \$35,160
Protocol to promote uptake of evidence on comparative effectiveness by P&T committee members.
 The aim of this inter-personnel agreement is to assess relationships between measures of COPD administered to veterans, and to develop a protocol to evaluate an intervention designed to enhance the uptake and integration of comparative effectiveness research into the P&T decision making process.

Pickard (PI) 08/09 – 08/10
 Takeda \$63,062 0 calendar (fellowship)
Takeda-UIC 1-year fellowship in health economics and outcomes research
 This is a 1-year fellowship funded by Takeda that provides training in health economics and outcomes research that includes onsite training at Takeda Pharmaceuticals International and coursework/research experience with faculty based in the Center for Pharmacoeconomics Research at the College of Pharmacy at UIC

2008

Pickard (PI) 11/01/08 – 08/31/09
 AHRQ \$276,000 2.4 calendar
 (master agreement 2006-00304/TO#4 2007-00894)
Development of a multicenter prospective study to assess the effectiveness of treatments for chronic obstructive pulmonary disease (COPD)
 The aims of this study are to: (1) evaluate whether tiotropium is associated with an increased risk of cerebrovascular events using a large observational database; (2) develop a protocol for a multicenter prospective study to assess the effectiveness of treatments for chronic obstructive pulmonary disease (COPD).

2007

Pickard (PI) 04/01/07 – 06/30/08
 Pfizer Direct \$70,847 / TC \$86,433 1.8 calendar
Estimation of a utility-based algorithm for the EORTC-QLQ.
 The aim of this study is to estimate a preference-based score based on the descriptive system for the EORTC QLQ, a cancer specific measure of HRQL.

Pickard (PI) 06/01/07 – 12/31/07
 AHRQ \$224,051 1.8 calendar
 (master agreement 2006-00304)
Comparative effectiveness of anticholinergic medications in patients with chronic obstructive pulmonary disease (COPD).
 The aim of this study is to evaluate the incremental effectiveness of anticholinergic medications in terms of impact on mortality, exacerbations and hospitalizations in patients with COPD.

Pickard (PI) 01/01/07 – 01/01/08
 Evanston Northwestern Healthcare \$86,433 0.5 calendar
A comparison of the impact of eleven types of cancer on quality of life.
 The aim of this study is to compare the quality of life burden between 11 types of cancer across different dimensions of health-related quality of life according to the FACT and EQ-5D.

Pickard (PI) 10/1/07 – 09/30/08 1.8 calendar
 Subcontract-Northwestern University \$27,227

Assessment of the use and outcomes with antithrombotic therapy following orthopedic surgery in VA-Phase 1

The aim of this study is to examine the use of LMWHs in VA patients undergoing orthopedic surgeries and compare outcomes and healthcare utilization between the different LMWHs.

Pickard (PI) 10/1/07 – 12/31/07 0.5 calendar
EuroQol Group \$9,444

Quality of life according to the EQ-5D in asthma and COPD

The objective of this study is to examine HRQL burden in COPD and asthma estimating EQ-5D utility scores by level of disease severity from the published literature and to summarize evidence of psychometric properties of the EQ-5D in asthma and COPD.

Pickard (PI) 07/01/07 – 06/30/09 -- calendar
TAP Pharmaceuticals \$116,563

TAP-UIC fellowship in health economics and outcomes research 2007-2009

This is a 2-year fellowship funded by TAP/UIC that provides training in health economics and outcomes research that includes enrollment in the MS degree program in Pharmacy Administration through the College of Pharmacy at UIC.

Pickard (PI) 07/01/07 – 06/30/10 -- calendar
Novo Nordisk \$173,649

Novo Nordisk & University of Illinois at Chicago fellowship in health economics and outcomes research

This is a 3-year fellowship funded by TAP/UIC that provides training in health economics and outcomes research that includes enrollment in the PhD degree program in Pharmacy Administration through the College of Pharmacy at UIC.

Pickard (PI) 10/01/06 – 07/30/07 4.0 calendar
Veteran Affairs Hines VA Hospital \$62,363

Drug treatment outcomes in COPD using models of medication exposure (IPA 3)

This interpersonnel agreement involves several collaborative projects with VA-based investigators. The primary aim is to examine of patterns medication use persistence and adherence prior to death in COPD patients for the management of respiratory symptoms, depression and pain.

Schumock (PI) 09/30/05 – 06/30/06 -- calendar
AHRQ Total \$499,999

Broad-based support for the DEcIDE Research Network (HSA290200500381, Task Order No. 4)

This is a multi-year task order from AHRQ that contracts our center to undertake a series of varied and inter-related work assignments related to research and program development relevant to the safety, effectiveness, efficiency and outcomes of health care items and services.

2006

Pickard (PI) 07/01/06 – 06/30/07 Donated effort
Rush University Total \$8,896

HRQL in patients with lupus

This study aims to validate a modified version of a UK-based QOL measure for SLE in US patients.

Schumock (PI) 10/01/05 – 09/30/06 1.0 calendar
AHRQ Total \$249,000

Outcomes of COPD management – DEcIDE network center task order TO 290-05-0038-01 (master agreement project ID 2 –EHC)

The aim of this project is to examine the effectiveness of theophylline to manage COPD using a large administrative database in the VA health system.

Pickard (PI) 01/01/06 – 12/31/06 Donated effort
EuroQol Foundation Total \$14,703

Use of the EQ-5D technology in studies of cancer: estimates of HRQL in subtypes of cancer and psychometric properties.

The objective of this study is to estimate the HRQL burden of various types of cancer as operationalized by the EQ-5D in the published literature and to summarize evidence of psychometric properties of the EQ-5D in subtypes of cancer.

Pickard (PI) 12/15/05 – 12/15/06 0.5 calendar
 EuroQol Foundation Total \$20,400
Rasch solutions to EuroQol problems: exploring IRT Models to estimate label equivalency and a valuation crosswalk for the EQ-5D.

The aims of this study are to examine the equivalency of 3 level and 5 level dimensions in a HRQL measure using modern psychometric techniques, and potentially develop a crosswalk between valuation sets for an indirect preference-based HRQL measure using IRT methods.

Pickard (PI) 05/01/06 – 04/30/07 2,4 calendar
 Veteran Affairs Hines VA Hospital Total \$25,000
Causes of death among veterans with COPD and asthma

The objective of this study is to examine multiple coded causes of death in patients with COPD, and determine if they differ between patients with longer-term and more recently diagnosed COPD.

2005

Pickard (PI) 10/01/05 – 09/30/06 4.0 calendar
 Veteran Affairs Hines VA Hospital Total \$46,038
Economic and clinical outcomes of pharmaceutical policies in the VA system – IPA 2

This study focuses on COPD and asthma treatment and management patterns in the VA system.

Pickard (PI) 02/01/05 – 09/30/05 1.8 calendar
 Veteran Affairs Hines VA Hospital Total \$17,840
Economic and clinical outcomes of pharmaceutical policies in the VA system

This study examines outcomes of treatment for COPD in the national database of the VA, using pharmacoepidemiologic methods to assess the safety of different combinations of medications.

2004

Witt (PI) 08/01/2004 – 07/31/2005 Donated
 American Cancer Society (Northwestern) \$19,671
Biological and Self-Reported Measures of Psychological Stress among Informal Caregivers of Patients with Prostate Cancer: A Pilot Study.

This pilot study is piggy-backed on my NCI recruitment of caregivers to determine the feasibility, performance, and comparability of stress biomarkers in caregivers of patients with prostate cancer as compared to caregiver-reported survey measures of psychological stress and how such measures are related to patient health outcomes. Moreover, we also seek to determine if sociodemographic differences in HRQL of veterans with prostate cancer can be explained in part by differences in caregiver burden.

Pickard (PI) 04/01/04 – 03/31/06 2.4 calendar
 National Cancer Institute \$153,815
Proxy Perspectives on Quality of Life in Prostate Cancer (R03 CA108395)

The aims of this study are to elicit proxy assessments of patients with prostate cancer in order: 1) To determine the extent of agreement between HRQL assessments performed by an informal caregiver from the perspective of the patient compared to their assessment of patient HRQL from the caregiver's own viewpoint; 2) To assess the extent of agreement between patient self-assessment in relation to two proxy assessed perspectives; and 3) To evaluate whether different proxy perspectives result in differences in HRQL assessment that are statistically significant and clinically meaningful.

Pickard (PI) 03/01/04 – 06/30/04 1.8 calendar
 University of Michigan (Subcontract) \$10,000

Prescription Drug Reimportation: A Survey of Product Safety, Patient Care, Pharmaceutical Innovation & Economic Implications

The aim of this study was to examine the attitudes and perceptions of national and state initiatives to reimport medications due to systematically higher prices in the US (prior to Medicare Part D)..

2003

Walton (PI) 09/01/03 – 09/01/05 0.5 calendar
Takeda \$107,000

Outcomes Analysis of Diabetes Treatments in Using VA Data

The aim of this study was to examine the safety and effectiveness of oral anti-hypoglycemic agents used to treat type II diabetes, and to examine the relationship between level of adherence and outcome using the national VA data.

Pickard/Lee (co-PIs) 09/01/03 – 02/01/04 0 calendar
Veteran Affairs Health Services R&D \$9,360

Proxy Perspectives on Health Related-Quality of Life: pilot study/structured cognitive interviews

We received pilot funds from the locally initiated projects (LIPs) fund at the VA to support qualitative data collective in the development of different proxy measures of HRQL.

Pickard (PI) 03/03 – 03/04 2.4 calendar
AstraZeneca \$34,700

Implications of Oral Direct Thrombin Inhibitors for Anticoagulation Clinics

In this study, we propose to evaluate the impact of a new class of drugs, oral direct thrombin inhibitors, on the structure and processes of care currently provided by anticoagulation clinics.

Schumock (PI) 01/01/02 – 12/31/03 0.5 calendar
Pharmacia \$52,484

Microalbuminuria and cardiovascular events: a systematic review of the clinical outcomes and estimation of potential economic impact (sponsored research contract- completed)

Pickard (PI) 03/02 – 09/02 0.5 calendar
EuroQol Foundation \$4,752

The Influence of Depression on Agreement between Proxy and Patient Self-Assessment in Stroke using the EQ-5D and SF-6D

The aims of this study are to examine whether depression in patients or caregivers systematically impacts the HRQL assessments they provide of the stroke patient.

Pickard (PI) 08/99 – 09/01 -- calendar
AstraZeneca/Institute of Pharmacoeconomics \$98,630

Responsiveness of HRQL Measures in Stroke.

The objectives of this study are to evaluate the longitudinal natural history of HRQL in stroke, assess the validity and responsiveness of several preference-based measures of health, and to compare the extent of agreement between patients and proxies.

Manuscript Reviewer (year beginning)

American Journal of Geriatric Pharmacotherapy (2005-)
Annals of Pharmacotherapy (2000-)
Archives of Internal Medicine (2002-)
Canadian Journal of Public Health (2000-)
Chest (2005-)
Current Medical Research and Opinion (2006-)
Expert Review of Pharmacoeconomics and Outcomes Research (2008-)
Health and Quality of Life Outcomes (2005-)
Journal of Clinical Epidemiology (2005-)
Journal of Social and Administrative Pharmacy (2001-)

Journal of General Internal Medicine (2004-)
 Journal of Medical Economics (2007-)
 Medical Care (2002-)
 Medical Decision Making (2005-)
 Pharmacoeconomics (2001-)
 Population Health Metrics (2004-)
 Quality of Life Research (2002-)
 Stroke (2003-)
 Value in Health (2005-)

Editorial Boards

Associate Editor, Quality of Life Research, 2013 – present
 Editorial Board, Medical Decision Making, 2013 – present
 International Advisory Board, Quality of Life Research (2006 – 2013)

Conference Judge/Moderator/Abstract Reviewer

2013	Session Chair, Oral Session 305 “To thine own self be true: quality of life among practitioners and researchers”. ISOQOL 20 th Annual Meeting, Miami FL, Oct 9-13, 2013.
2013	Moderator, Plenary Session, “New Horizons in Quality of Life Research” ISOQOL 20 th Annual Meeting, Miami FL, Oct 9-13, 2013.
2008 - present	Biennial Cancer Survivorship Research Conference, Office of Cancer Survivorship, NIH/NCI, abstract reviewer.
2005 - present	American Pharmacist Association, abstract/paper reviewer.
2005 - present	Society of Behavioral Medicine, abstract reviewer, quality of life track.
2005 - present	ISOQOL annual conference, abstract reviewer & poster judge.
2003 - present	EuroQol annual scientific plenary, abstract reviewer.
2002 - present	EuroQol annual Scientific Plenary, paper discussant.
2003 - present	ISPOR annual conference, abstract reviewer.
2006	ISOQOL – travel scholarship award committee.
2007	ISPOR – 12 th annual conference session moderator

External Referee: Grants, Technical Documents, Tenure and Promotion

2014	Dutch Cancer Society
2014	External Reviewer, Hong Kong Research Grants Council
2013	UIC CCTS Pilot Grant Program
2011 - present	<i>Reviewer</i> , promotion and tenure, various universities.
2011	<i>Reviewer</i> , United Kingdom (UK) National Institute for Clinical Excellence (NICE), Decision Support Unit, technical support document.
2010	<i>Ad hoc reviewer</i> , Health Care Research Training Study Section, Agency for Healthcare Research and Quality
2010	<i>Ad hoc reviewer</i> , Special Emphasis Panel – R24 expansion of research capability to study comparative effectiveness in complex patients, Agency for Healthcare Research and Quality
2004, 2009	<i>Ad hoc reviewer</i> , Health Care Efficiency Research Program, Netherlands Organization for Health Research and Development (ZonMw)
2008, 2012	<i>Ad hoc reviewer</i> , Medical Research Council, United Kingdom Department of Health
2005 - present	Grant reviewer, EuroQol group
2005	Life Science Review Panel, UIC 2010 Seed Grant

Teaching/Advising – Professional (PharmD) Program

Pharmacy 344	Social and Behavioral Pharmacy (2 credit hours). Spring 2014. Course co-ordinator and instructor.
Pharmacy 355/455	Drug Information and Statistics (4 credit hours). Spring 2003-2013. Hypothesis testing; testing differences between groups, emphasis on t-tests (3 lecture hours, 9 hours of recitation). PharmD Professional program, College of Pharmacy, UIC, Chicago.
Pharmacy 356	Principles in Pharmacoeconomics and Drug Treatment Outcomes. Fall 2001, Spring 2003-2014. Lecture hours (2), Health-related quality of life and Humanistic Outcomes. Recitations: scoring of health status measures (2 hours); issues in HRQL measurement (2 hours). PharmD Professional program, College of Pharmacy, UIC, Chicago.
Pharmacy 380	Independent Research Projects. Spring 2002-present. Professional Program
Pharmacy 388	Advanced Specialty Clerkships, 2002-present. Preceptor in Pharmacoeconomics (4 th year PharmD students).
Pharmacy 485	Medication Use and the Canadian Health Care System. Lecture hours (3), Critiquing Economic Evaluations of Pharmaceuticals; Drug-Related Mortality and Morbidity; Pharmaceutical Care. Spring 1999 and 2000; BScPharm Professional program, Faculty of Pharmacy, University of Alberta.
Pharmacy 489	Therapeutics. Lecture hours (1), Sampling Methods in Research, Mar 1998; Measurement issues in Research, Mar 1999, Mar 2000, BScPharm Professional program, Faculty of Pharmacy, University of Alberta.

Teaching – Graduate Program

PSOP 525	Medication, Illness and Identity (3 credit hours). This is a core course that I co-ordinate in our graduate program (with Dr. Touchette) that focuses on research approaches to examining social and behavioral aspects of pharmaceutical care. Spring 2014.
PSOP 579	Advanced methods in outcomes research and grant writing (3 credit hours). In this elective PSOP course, I serve as coordinator and primary lecturer that covers advanced topics on outcomes research. Several guest faculty discuss their research programs and their approach to funding support, and the main project is development of a grant proposal to a federal agency. Spring 2006; Spring 2008; Spring 2010; Spring 2012. Planned for Spring 2015.
PSOP 571	Principles of Pharmacoeconomics. Lecture hours (3). In this core PSOP course, I discuss the role of health-related quality of life measurement in economic evaluations of health care. Fall 2002-present.
PSOP 426	Pharmacoepidemiology (2 credit hours). In this class coordinated by Dr. Todd Lee, I instructed on the external validity of comparative effectiveness studies until the course became primarily online. Summer 2010-11.
Seminar	Center for Pharmacoeconomic Research: Monthly Seminar Series on Pharmacy/Pharmaceutical Outcomes Research. (2005-2009)

Advisees

Graduate Students

Name	Time Period	Degree	Thesis Title	Role
Mehul R. Dalal	2002-05	PhD	The impact of longitudinal patterns depression on functional disability	Primary Advisor and Chair, Dissertation Committee
Zhixiao Wang	2003-06	PhD	Medication adherence in patients with diabetes, hypertension and hyperlipidemia	Examiner, Preliminary Examination Committee
Shih-Ying (Audrey) Hung	2004-06	MS	The impact of pain and depression on caregiver assessment of quality of life in stroke	Primary Advisor and Chair, Thesis Committee
Caitlyn Wilke	2005-07	MS	Statistical implications of utility-weighted and unweighted measures of HRQL measures	Primary Advisor and Chair, Thesis Committee
Eunmi Jung	2005-07	MS	Medication adherence and persistence prior to death in patients with COPD	Primary Advisor and Chair, Thesis Committee
Hsiang-Wen (Margaret) Lin	2005-08	PhD	Determinants of pharmacist knowledge, attitudes and performance of counseling on dietary and herbal supplements	Primary Advisor and Chair, Dissertation Committee
Xiaoqing (Frank) Liu	2007-10	PhD	Evaluating the economic and health impact of Medicare Part D on beneficiaries	Dissertation Committee Member
Caitlyn Wilke	2007-10	PhD	Relationship between time windows of medication exposure and outcomes in comparative effectiveness research	Primary Advisor and Chair, Dissertation Committee
M Charisse DeLeon	2008-11	MS	Impact of insurance status on medication use in children with ADHD	Dissertation Committee Member
Xiaochen Luo	2008-11	MS	Efficiency of estimation with the US population median-based EQ-5D index: findings from the Medical Expenditure Panel Survey	Dissertation Committee Member
Yash Jalundhwala	2008-11	MS	Logical inconsistencies as a criterion for selecting health states in EQ-5D valuation studies.	Dissertation Committee Member
Fang-Ju Lin	2010-13	PhD	Condition specific applications for the valuation of health	Primary Advisor and Chair, Dissertation Committee
Jennifer Samp	2011-12	MS	Economic evaluation of the impact of medication errors reported by clinical pharmacists (Capstone)	Advisor/Reader
Yash Jalundhwala	2011-present	PhD	The role of psychological disposition in drug-related health behaviors and quality of life.	Primary Advisor
Iulia Ursan	2013-present	MS	Provider, patient, and caregiver perspectives on barriers to access to care.(Capstone)	Primary Advisor
Jennifer Samp	2012-present	PhD	TBD	Advisor/Committee Member

Yu-Ting Hung	2014-present	PhD	TBD	Primary Advisor
Ernest Law	2014-present	PhD	TBD	Primary Advisor
Ruixuan Jiang	2015-present	PhD	TBD	Primary Advisor

FELLOWS

Name	Dates	Degree	Role	Current Position
Juan Blackburn, MD, MBA, MPH	2003-05	MPH	Co-advisor, Fellowship in Pharmacoeconomics	Manager, Latin America, Baxter Laboratories
Melissa Butler, PharmD, MPH	2003-04	MPH	Co-advisor, Fellowship in Pharmacoeconomics	Scientist, Kaiser Permanente
Hayley Park, PharmD, MBA	2004-05	MBA	Co-advisor, Fellowship in Pharmacoeconomics	Director, Outcomes Research, McKesson
Robert Wittenberg, PharmD	2007-08	--	Primary Advisor, Fellowship in Pharmacoeconomics and Outcomes Research	Senior Manager, Lundbeck
Caitlyn Wilke, MS	2007-10	PhD	Primary Advisor, Fellowship in Pharmacoeconomics and Outcomes Research	Senior Scientist, Pharmedit North America
Charisse De Leon, MS	2008-09	MS	Primary Advisor, Fellowship in Pharmacoeconomics and Outcomes Research	Manager, Homecare company.
Yoojung Yang, PharmD	2009-11	MS	Primary Advisor, Fellowship in Pharmacoeconomics and Outcomes Research	Senior Manager, Baxter
Firas Dabbous, MS	2009-10	--	Primary Advisor, Fellowship in Pharmacoeconomics and Outcomes Research	PhD program, UIC
Rima Tawk, PhD	2010-12	--	Primary Advisor, Fellowship in Pharmacoeconomics and Outcomes Research	Assistant Professor, Florida A & M
Jennifer Samp, PharmD	2011-13	MS/PhD	Primary Advisor, Fellowship in Pharmacoeconomics and Outcomes Research	Senior Manager, AbbVie
Hari Patel, PharmD	2012-14	PhD	Primary Advisor, Fellowship in Pharmacoeconomics and Outcomes Research	Consultant, Takeda; current PhD student
Iulia Ursan, PharmD	2013-15	MS	Primary Advisor, Fellowship in Pharmacoeconomics and Outcomes Research	Current Student

Ernest Law, PharmD	2014-16	PhD	Primary Advisor, Fellowship in Pharmacoeconomics and Outcomes Research	Current Student
-----------------------	---------	-----	--	-----------------

Honors College

Name of Student	Start and completion dates	Program	Role	Notables
Brian Oca	2004-07	Pre-pharmacy	Advisor	UIC COP Class 2011
Matthew Sargent	2005-08	Pre-pharmacy	Advisor	UIC COP Class 2012
Margareta Zwolenik	2006-09	Pre-pharmacy	Advisor	UIC COP Class 2013
Yevgeniy Raskin	2009-11	Pre-pharmacy (GPPA)	Advisor	UIC COP Class 2014 HC Undergraduate Research Award
Ryan Tabor	2009-12	Pre-pharmacy	Advisor	UIC COP Class 2016
Joseph Dang	2012-2014	Pre-pharmacy	Advisor	Current UIC COP
Sundip Singh	2012-present	Pre-pharmacy	Advisor	

Invited Presentations

Ask a pharmacist about your medication issues (speaker). *Unsung Heroes Presentation Series*, Schizophrenia Society of Alberta, Christchurch Parish, Edmonton, AB. Oct 1999; Aug 1998

“How to Evaluate Pharmacoeconomic Literature”. *Pharmacoeconomics for Pharmacists*, Continuing Education Program for the Alberta Pharmaceutical Association, 2 lecture hours. November 20, 1999.

“Drug Utilization Review (DUR): Design and Implementation Issues.” Invited speaker, presented to the Alberta Management Committee on Drug Utilization. January 20th, 2000, College of Physicians and Surgeons, Edmonton, Alberta.

“Canadian VAS-based Valuations of the EQ-5D health states and Comparison of European and Canadian Valuations.” Euroqol BioMed group, September 30th, 2000, Pamplona, Spain.

“Agreement between self- and proxy-assessment in stroke: a comparison of generic HRQL measures.” Oral presentation at International Society of Quality of Life (ISOQOL) conference, November 6-9th, 2002, Amsterdam Netherlands. Also presented at the Colleges of Pharmacy at the University of Minnesota (April 22nd 2001); University of Southern California (April 24th 2001); University of Illinois at Chicago (May 10th 2001); University of Western Virginia (May 12th 2001).

“Comparing the responsiveness of generic measures in stroke patients using clinical anchor-based approaches”. Invited speaker, The Center for Outcomes Research and Education (CORE) Evanston/Northwestern University Speaker Series in Quality of Life Outcomes in Chronic Illness, Chicago, Illinois, Feb 19th, 2002.

“Extra patient considerations in evaluating restrictive drug reimbursement policy.” Oral podium presentation at Annual Meeting of the Canadian Association for Population Therapeutics, April 22-24th 2002, Toronto, Canada.

“The influence of culture on health-related quality of life.” Invited speaker. American College of Clinical Pharmacists (ACCP) 2002 Annual Meeting, Outcomes PRN. October 20-23, 2002, Albuquerque, New Mexico, USA.

“Responsiveness of Generic Health-Related Quality of Life measures in Stroke.” Oral presentation at International Society of Quality of Life (ISOQOL) conference, October 29-November 2nd, 2002, Orlando, Florida.

“A novel approach to assessing agreement between raters of multi-dimensional measures at the individual level using fuzzy set theory.” Oral presentation at International Society of Quality of Life (ISOQOL) conference, November 12-15th 2003, Prague, Czech Republic.

“Pharmaceutical Drug Importation: Attitudes and Intended Behaviors of US Pharmacists.” Invited speaker, Health Services Research and Policy Seminar Series, Northwestern University/VA Midwest/Center for Health Studies/Evanston NWU CORE/Rehabilitation Institute of Chicago/Buehler Center for Aging, Chicago, IL, April 8th, 2004.

“Reimportation of Pharmaceuticals: Pharmacist Perceptions in the US.” Invited speaker, podium presentation at conference on “Innovation and Drug Reimportation: The cost, the value, the trade-offs”. April 18-20th, 2004. JW Marriott and National Press Club, Washington, DC.

“CEC Workshop: A Practical Approach to Pharmacoeconomics” Co-organizer and presenter. August 3rd, 2004, St. Louis, Missouri.

“Proxy perspectives on HRQL: a general conceptual framework applied to prostate cancer.” Invited speaker, Health Services Research and Policy Seminar Series, Northwestern University/VA Midwest/Center for Health Studies/Evanston NWU CORE/Rehabilitation Institute of Chicago/Buehler Center for Aging, Chicago, IL, April 25th, 2005.

“Proxy Assessment of HRQL of Prostate Cancer: the importance of perspective” (poster). National Institutes of Health/National Cancer Institute – Small Grantees Meeting, Bethesda, MD. May 8 to 10th, 2005.

Proxy perspectives on HRQL: applying a conceptual framework to prostate cancer. University of Wisconsin-Madison School of Medicine and Public Health. Feb 12th 2007.

“Utility measures: role in comparative effectiveness research and development of a QLQ-C30 based cancer-specific measure”. Present at Pfizer, New London, CN, March 24, 2008.

“The need to understand the value of medications”. Center for Drug Evaluation, Taipei, Taiwan, April 30th, 2008.

“Outcomes research and demonstrating the value of the pharmacist”. College of Pharmacy, National Taiwan University, Taipei, Taiwan, May 1, 2008.

“Importance of pharmacy practice-based research”. College of Pharmacy, Cheung Kung University, Tainan, Taiwan, May 1, 2008.

“Implications of the outcomes research movement for global health care and its applications to the field of pharmacy”. 50th Anniversary Celebration, College of Pharmacy at China Medical University (CMU), Taichung, Taiwan, May 4, 2008.

"Advising fellows using the ISPOR fellowship guidelines". 14th Annual ISPOR international conference, Toronto, Canada, May 7, 2008.

"Health economics and outcomes research: the science behind the value proposition". Baxter, Chicago, IL. October 6, 2008.

"Comparative effectiveness: a national agenda and applications; Critical appraisal of the pharmacoeconomic studies; Health economics and outcomes research: the science behind the value proposition". Meiji Pharmaceutical University, Tokyo, Japan, March 1-8, 2009.

"The new emphasis on comparative effectiveness in medical research". Health Outcomes Seminar Series. Institute for Health Research and Policy, April 23, 2009.

"Comparative effectiveness research: applications and relevance to pharmacy". National Webinar sponsored by Agency for Healthcare Research and Quality [cosponsored by ACCP, AMPC, APhA]. September 9, 2009.

"Health economics and outcomes research: current trends and future paths". American Managed Care Pharmacy UIC student chapter meeting, Sept 17, 2009.

"Introduction to comparative effectiveness research: applications to managed care and industry". Managed Markets Fall Meeting, Carlsbad, CA, September 21, 2009.

"Comparative effectiveness research: what is it and how is it applicable to pharmacy?" American College of Clinical Pharmacy. Annual conference, Anaheim, CA, October 20, 2009.

"Prioritizing comparative effectiveness topics in COPD". Chicago-area consortium for comparative effectiveness research. Blue Cross Blue Shield Association, Chicago, IL, April 19, 2010.

"Introduction to quality of life and considerations when choosing a quality of life instrument". American College of Clinical Pharmacy. ACCP Midyear conference, Charlotte, North Carolina, April 26, 2010.

"Assessing Quality of Life Using EQ-5D". Transthyretin Amyloidosis Outcomes Survey (THAOS) Scientific Advisory Meeting, Pfizer. Manhattan, New York, May 5, 2011.

"A framework for conducting pharmacoeconomic evaluations." Genzyme Scientific Advisory Meeting. Pittsburgh, PA, October 15, 2011.

"Developments in assessing and valuing health using patient-reported outcome tools". Chicago regional chapter of ISPOR, Chicago, IL, May 2, 2012.

"Developing, using and valuing a more refined EQ-5D: the EQ-5D-5L". Speaker. Symposium, ISPOR, Washington DC, June 2-6 2012.

"International use of the EQ-5D". European Society for Medical Decision Making. Oslo Norway. June 12-13, 2012.

"Barriers to pharmacogenomics testing in underserved communities". Annual conference of the Chicago colorectal consortium (CCCC). American Cancer Society Illinois Chapter, Chicago, IL. February 22, 2013.

"The importance of leadership in academia and health care". Inaugural lecture, leadership series, Marmion Academy, Aurora, IL, September 22, 2013.

"Recent developments in valuing health" Health Outcomes Seminar Series at UIC. October 17, 2013.

"Outcomes research and its role in evaluating the value of medications." Honors College Seminar, University of Illinois at Chicago, Honors College, Chicago, IL, November 11, 2013.

"New developments in valuing health: directions for the EQ-5D" International Society for Quality of Life, Miami, FL, Oct 9-13, 2013.

"Incorporating Patient-Reported Outcome Measures in Reimbursement Decision-Making: Measuring and Valuing Health". 25th Annual Meeting, Canadian Agency for Drug and Technologies in Health (CADTH), April 5-7, 2014.

"Mapping health utilities: where does this road lead?" International Society for Pharmacoeconomics and Outcomes Research, Chicago-Regional Chapter Webinar, Oct 7th, 2014.

"Scientific Directions for the EuroQol Group." International Society for Pharmacoeconomics and Outcomes Research, International Annual Conference, May 18, 2015.

"New developments in measuring health". Rockford College of Pharmacy Seminar, August 24, 2015.

"Roundtable discussion: debates in approaches to health preference measurement". ISOQOL, Vancouver, Canada, October 14-18, 2015.

"Health utilities: measurement and valuation approaches." National webinar for ISPOR Student Chapters. October 28, 2015.

"PROMs in Alberta: Introduction to the EuroQol Group" First meeting of the Alberta PROMs and EQ-5D Research and Support Unit (APERSU). Canmore, Alberta, October 20, 2015.

(upcoming) *"Variation in health state preferences across populations: East doesn't meet West"*. 27th Annual Meeting, Canadian Agency for Drug and Technologies in Health (CADTH). Symposium. Ottawa, Canada, April 5-7, 2016.

(upcoming) *"Engaging patients and general public in health technology assessment: measuring and valuing health preferences"*. Workshop. 2016 Health Technology Assessment International Annual Meeting, Tokyo, May 10-14, 2016.

(upcoming) *"Developments in preference-based measures of health: scoring approaches and guidance"*. Workshop. ISOQOL international meeting in Copenhagen, Denmark. October 19-22, 2016

Research Featured in Media

"Study: pharmacies that produce compounded drugs in Illinois are not tracked" (Feb 26, 2016). Interview with Chicago Tonight. Website. Available at:
<http://chicagotonight.wttw.com/2016/02/26/study-pharmacies-produce-compounded-drugs-illinois-not-tracked>

"Mixing drugs and herbal remedies may pose a major health risk researchers warn". (Nov 2, 2012) Globe and Mail.

<http://m.theglobeandmail.com/life/health-and-fitness/health/mixing-drugs-and-herbal-remedies-may-pose-a-major-health-risk-researchers-warn/article4854590/?service=mobile>

(The Globe and Mail) is a nationally distributed Canadian newspaper, with a weekly readership of approximately 1 million).

Also featured in Blisstree (weblog); Medical News (online); Daily Telegraph (UK – readership upwards of 1 million); (Best Health News – BMJ); Nursing News.

<http://blisstree.com/eat/supplements/herbal-health-remedies-interact-with-medicine-411/>

<http://www.medicalnewstoday.com/articles/251953.php> (Editor's choice)

<http://www.telegraph.co.uk/health/healthnews/9636982/Herbal-remedies-linked-to-drug-side-effects.html>

<http://besthealth.bmj.com/x/news/683861/news-item.html>

<http://www.nursingtimes.net/home/clinical-zones/medicine-management/effects-of-supplements-on-medicines-dangerous/5051095.article>

“Facts in Scientific Drug Literature May Not Be, Study Finds” UIC News, ranked in TOP 10 news releases in Newswise.

“Study finds retractions in drug literature often indicative of scientific misconduct” (interview with Celeste Headlee on the Takeaway, national public radio, May 31, 2012).

<http://www.thetakeaway.org/2012/may/31/study-studies-finds-retractions-drug-literature-often-indicative-misconduct/>

“Facts in Scientific Media may not be so.” Science Daily, May 29, 2012.

<http://www.sciencedaily.com/releases/2012/05/120529181145.htm>

“Local pharmacists support drug imports if they oversee process.” Chicago Tribune, Business B3, December 2, 2004.

“Survey finds community pharmacists not opposed to drug imports if safety, effectiveness regulated.” UIC News, December 1, 2004.

Pharmacists want role in importation, study shows. UIC Press release, November 23, 2004.

Even local pharmacists may support imported drugs. Senior Journal, November 24, 2004.

<http://www.seniorjournal.com/NEWS/Medicare/4-11-24Pharmacists.htm>

Pharmacists believe consumer interest in importation will continue. Pharmacy Today (official publication of the American Pharmacists Association). Volume 10, No. 11. November 2004.

Lifting the Pharmacist's Voice. UIC Pharmacist. Pg 13. 2003-2004.

Generic drug policy reducing Alberta's costs. Medical Post, pg 41. November 28, 2000.

Checking up on stroke recovery. Edmonton Journal pg B1, B8. September 7, 2000.

Cost and effectiveness of anti-psychotic medications. 630 CHED (AM radio) with Leslie Primeau, November 1997.

Service

University

2013 – present	Conflict Management Committee
2004 – present	Fellow of the Honors College
2004 – present	Faculty advisor, UIC ISPOR Student Chapter
2004 - 07	Graduate College Awards Committee, UIC, 3-year elected term
2003 - 05	Faculty Senate, University of Illinois at Chicago, 3-year elected term
2004	Organizing committee, UIC conference on drug expenditures

College

2014	Assessment/Admissions Committee (ad hoc)
2014 - present	Advisory Board, T32 AT007533 Research Training in Natural Product CAM
2010-12; 2013-15	Executive committee
2007 – 09	Committee on committees (chair 2008-09)
2006 - 07	Student-faculty relations committee
2006	Faculty search committee, Dept. Pharmacy Administration
2005 – present	Assistant Director, Center for Pharmacoeconomic Research, College of Pharmacy, UIC, Chicago, IL, USA.
2004, 2005	Interviewer, admissions to PharmD program
2002 - 2006	Image and Public Relations Committee

2004 – present Faculty advisor, Pharm.D. professional program
2002 – present Preceptor, advanced clerkships

Department

2013 - present Director of Graduate Studies
2008 – 2010 Tenure and promotion committee, Dept of Pharmacy Practice
2005 Departmental research support - needs assessment
2004 Research review committee for pharmacy residents.
2003, 2004 Feasibility assessment, PharmD/PhD in pharmacy practice

Professional

2014 – present Clinical Care Advisory Group (CCAG), Illinois Department of Human Services.
2013 Program Co-chair, 20th Annual International Meeting of ISOQOL, Miami, 2013.
2012 - present Chair, Data Archive Working Group, EuroQol group.
2012 Leadership retreat member, ISPOR vision 2020 Implementation Task Force
2011 - 2012 Program Co-chair, Annual Scientific Plenary of the EuroQol Group, Oxford (2011);
2010 - present Deputy Chair, Executive Committee, EuroQol Group
2009 - present National Council of faculty advisors for student chapters, ISPOR
2009 - 2010 Past-President, Chicago regional chapter ISPOR
2008 - 2009 President (elected), Chicago regional chapter ISPOR
2007 Fundraising Chair, Bi-annual Midwest Social and Administrative Pharmacy conference (UIC host)
2006 - 2012 Chair, Condition-specific program task force, EuroQol Group
2005 - present Member, Executive Committee, EuroQol Group Foundation, 3-year elected terms
2004 Conference Chair, organizing committee for 21st Plenary Meeting of the EuroQol Group, Chicago, IL, September 16-18th 2004.
1998 - 1999 Member, Pharmacy Collaboration Group (Alberta Health/ Capital Health Authority/ Calgary Regional Health Authority/ Institute of Health Economics) Strategies for Provincial Formulary Coordination
1994 - 1996 Member, Alberta Drug Utilization Review Steering Committee